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Background: Diabetic retinopathy (DR) is a microvascular complication of 
diabetes that leads to visual impairment in the adult population with effective available 
therapy. Micro-Ribonucleic acids (miRNAs) are small (∼22 nucleotides) expressed 
RNA molecules that do not code for protein. They affect the expression of the target 
gene at the post-transcriptional level, hence, affecting several cellular processes. 
Clinical and experimental studies demonstrated that miRNAs are implicated in the 
pathogenesis of diabetic retinopathy. We identified hsa-miR-146a-5p is differentially 
expressed in human retinal microvascular endothelial cells (HRECs) under 
hyperglycemic conditions treated with adiponectin using RNA-seq for miRNA and 
qRT-PCR.  
Aim and objectives: To explore the impact of hsa-miR-146a-5p in 
hyperglycemia condition in vitro using HRECs and evaluate whether miR-146a-5p 
could mimic adiponectin's actions and effects in ameliorating the hyperglycemic effect 
in HRECS in vitro. 
Methods: HRECs were treated with 25 mM glucose, then transfected with a 
low dose of 10 nM or high dose of 50 nM of miR-146a-5p mimic to overexpress the 
miR-146a-5p.  Moreover, we transfected HRECs using 10 nM of miR-146a-5p 
inhibitory to silence the expression. Apoptosis and oxidative stress were evaluated. 
Total RNA was extracted from different HRECs-treated groups, and the gene 
expression of miR-146a-5p, TRAF6, TNF- , ICAM-1, PPAR-  and antioxidant 
 
iv 
enzymes were evaluated using qRT-PCR.  Further, we utilized RT-PCR profile array 
technology to explore the gene panel for inflammatory, cytokine receptor molecules 
and angiogenesis in HRECs under hyperglycemic conditions transfected with 50nM 
miR-146a-5p mimic. Bioinformatic analysis tools were used to explore the impact of 
50 nM miR-146a-5p mimic transfection on inflammatory, oxidation, and angiogenesis 
pathways. 
Results and discussion: Transfection with miR-146a-5p inhibitory and 10 nM 
of miR-146a-5p mimic upregulated the expression of TNF-α, ICAM-1, and ROS 
production in HRECs, indicating a pro-inflammatory effect. Transfection of HRECs 
with 50nM miR-146a-5p mimic revealed anti-inflammatory impact and significantly 
reduced the expression of TRAF-6, TNF-α, and ICAM-1, whereas PPAR- α expression 
was not affected. Pathway analysis demonstrated a pleiotropic effect of miR-146a-5p 
miRNA on gene expression via different pathways such as Il-17 signaling pathway, 
IL-8 Signaling, Toll-like Receptor Signaling, PPAR Signaling, and IL-6 Signaling, and 
also via inhibiting several transcription factors such as HMGB1, Jun, STAT4, NFKB1, 
and RELA. 
Conclusion: These results propose that miR-146a-5p could be involved in the 
amelioration of hyperglycemia-induced endothelial inflammation. High expression of 
miR-146a-5p and its anti-inflammatory, anti-oxidant, and anti-angiogenesis impact 
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CHAPTER 1: INTRODUCTION 
Diabetes is a chronic disease characterized by hyperglycemia, and as of the year 
2019, about 463 million people worldwide have either type 1 or type 2 diabetes, and 
the numbers are expected to reach 700 million by the year 2045 (IDF, 2019). The 
constant status of hyperglycemia in diabetes leads to many complications categorized 
as macrovascular such as coronary artery disease or microvascular complications like 
nephropathy and retinopathy.  
 Diabetic retinopathy (DR) is a serious microvascular complication of diabetes, 
and it is the main cause of visual disability and blindness among the working-age 
population (20–65 years) (Qiaoyun Gong, Xie, Liu, Li, & Su, 2017). It is estimated that 
the probability of a person with type 1 diabetes developing DR is 75%, while a type 2 
diabetes person has a chance of 50% to suffer from DR (Cohen & Gardner, 2016). A 
study reported that DR is responsible for 4.8% of the total blindness cases worldwide 
(Al-Kharashi, 2018). In addition, DR is called the silent cause of blindness (Srivastava 
et al., 2019) because no symptoms are observed in the early stages, and visual 
impairment begins when DR has already progressed (Al-Kharashi, 2018), which is 
characterized by vascular abnormalities in the retina (W. Wang & Lo, 2018). In the 
later stage of DR, the severe retinal ischemia condition due to blockage of blood vessels 
leads to the secretion of vascular endothelial growth factor (VEGF), stimulating the 
formation of new blood vessels in a process known as neovascularization 
(angiogenesis) (Tarr, Kaul, Chopra, Kohner, & Chibber, 2013). The pathogenesis of 
DR is complicated, and the exact process is incompletely understood and remains 
controversial due to the involvement of multiple factors (Q. Gong & Su, 2017).  
The primary factor of DR is the consistent state of hyperglycemia, followed by 
numerous secondary mechanisms and pathways that contribute to disease development 
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and progression (W. Wang & Lo, 2018). Oxidative stress and inflammation have been 
widely reported to be of the main factors involved in developing DR. Emerging studies 
reported numerous protein-coding and non-coding genes related to hyperglycemia to 
have a role in DR development and progression. Among the non-coding RNAs 
(ncRNAs), miRNAs (miRNAs) function and involvement in DR pathology have been 
widely studied. MiRNAs are biomarkers and molecules with regulatory roles in several 
biological processes (Condorelli, Latronico, & Cavarretta, 2014). Interestingly, 
miRNAs are reported to regulate pro-inflammatory pathways (E.-A. Ye & Steinle, 
2017b), expression of VEGF, and endothelial cells' response to VEGF (Suárez & Sessa, 
2009) and therefore can regulate DR. 
One of the largely studied anti-inflammatory miRNAs is miR-146a-5p, which 
is reported to downregulate activation of NF-κB by targeting its signaling molecules 
IRAK1, TRAF6, and MyD88 (Ma, Becker Buscaglia, Barker, & Li, 2011; L. Zhang, 
Dong, Tang, Li, & Zhang, 2020) and reduce expression of adhesion molecule ICAM-1 
on epithelial cells (P. Zhuang, Muraleedharan, & Xu, 2017). Many studies 
demonstrated downregulation in miR-146a-5p expression in hyperglycemic conditions; 
therefore, the downregulation of miR-146a-5p plays a potential role in the pathogenesis 
of DR by enhancing inflammation in the vascular system of the retina. Adiponectin is 
another factor that is reported to be decreased in hyperglycemia and to have a potential 
role in DR. In a study by Al-Sadeq, 2018, results showed that exposing of HRECs to 
adiponectin in hyperglycemic condition increases miR-146a-5p expression (Al-Sadeq, 
2018). Hence, we predicted that miR-146a-5p  might prevent inflammation in HRECs 
by mimicking adiponectin action and increase the PPAR-α expression, which is 
involved in the genesis of DR. 
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Currently, there are several therapeutic options for DR, such as eye surgery, 
laser photocoagulation, anti-VEGF injections, steroids, and PPAR-α agonist (Duh, Sun, 
& Stitt, 2017; Mohamed, Gillies, & Wong, 2007). However, the failure of a successful 
response to these available treatments is common among DR patients (Stewart, 2016). 
Therefore, researchers focus on studying miRNAs association with DR through gene 
regulation to develop novel and effective molecular therapeutic strategies for the 
disease development, progress, and maintenance. 
In this study, we aimed to extend the previous work to explore the impact of 
hsa-miR-146a-5p on diabetic milieu and to highlight the impact of using miR-146a-5p 
to mimic adiponectin actions, especially in diabetic subjects who are characterized by 
low adiponectin levels. We exposed HRECs to 25mM glucose for 96 hours and then 
transfected the cells with miR-146a-5p mimic and inhibitory using low dose (10 nM) 
and high dose (50nM) to examine the effect on  1) inflammatory cytokine and adhesion 
factors including PPAR-α, TNF-α, ICAM-1 and TRAF-6 2) ROS production and 3) 
cell viability and apoptosis rate. Our data revealed the anti-inflammatory role of miR-
146a-5p in DR and hypothetically in other vascular complications of diabetes by 
decreasing TNF-α, ICAM-1, and TRAF6 expression. In addition, our data showed no 
significant effect of miR-146a-5p mimic on the expression of PPAR-α. Therefore, our 
hypothesis that miR-146a-5p may regulate inflammation mainly through the PPAR-α 
pathway needs further investigation. Finally, our study's findings show that determining 
the effective dose of miR-146a-5p is essential since it was demonstrated that using a 
low dose could result in adverse effects. Hence, bioinformatic analysis using 
inflammation and angiogenesis profiles was performed, in addition to the assessment 
of oxidative stress genes to explore the possible pathways and the mechanistic 
regulation of hsa-miR-146a-5p in HRECs exposed to the hyperglycemic condition. 
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CHAPTER 2: LITERATURE REVIEW 
Diabetic retinopathy (DR) 
DR has resulted from abnormal retinal blood vessels (Duh et al., 2017), and it 
is classified into an early non-proliferative diabetic retinopathy (NPDR) and an 
advanced proliferative diabetic retinopathy (PDR) (Solomon et al., 2017). NPDR is 
further classified into three stages mild, moderate, and severe (Martinez & Peplow, 
2019). During NPDR, the tiny blood vessels of the retina swell, leading to the 
appearance of microaneurysms. Consequently, the blood capillaries rupture, and the 
vascular permeability increase due to the break of the tight junctions between the 
capillaries leading to hemorrhage and accumulation of fluid in the retinal vasculature 
(Zaki et al., 2016). This is followed by swelling and blockage of the vessels that nourish 
the retina (Martinez & Peplow, 2019). As the disease progress, in PDR, the severe 
retinal ischemia due to blockage of blood vessels leads to the secretion of growth factor 
VEGF stimulating the formation of new blood vessels, in PDR, the severe retinal 
ischemia due to blockage of blood vessels leads to the secretion of growth factor VEGF, 
stimulating new blood vessels formation in a process known as neovascularization 
(angiogenesis) (W. Wang & Lo, 2018). The newly formed abnormal fragile blood 
vessels can bleed into the vitreous, causing vitreous hemorrhage-, and tissue contract 
can cause tractional retinal detachment or distortion, both together lead to severe vision 
impairment (Kollias & Ulbig, 2010; Weinreb, Aung, & Medeiros, 2014). The reason 
that can complicate the condition and lead to complete vision loss in DR patients is 
diabetic macular edema (DME), which can occur at any stage of the disease (Cohen & 
Gardner, 2016; W. Wang & Lo, 2018). DME is the swelling of the macula due to the 




Epidemiology and risk factors 
The number of people suffering from DR worldwide was estimated to be 93 
million, according to a pooled meta-analysis study performed in 2012 (Yau et al., 2012). 
Moreover, another meta-analysis published in 2016 reported that as of 2010, 3.7 million 
people globally had a visual impairment or were blind because of DR, a data that 
reflected 64% and 27% increase in each group respectively compared to 1990 (Leasher 
et al., 2016). Furthermore, by the year 2045, 10% of the world adult population are 
predicted to develop DR as a complication of diabetes which is estimated to affect 700 
million people leading to disastrous social and economic consequences  (IDF, 2019). A 
recent review article published in 2019 which studied the global prevalence of DR 
based on studies performed between 2015 and 2018 showed that on average, 27% of 
all diabetes patients had a form of DR, with NPDR being the most common, accounting 
for 25% (Thomas, Halim, Gurudas, Sivaprasad, & Owens, 2019).  
The factors that increase the risk of developing DR are several, including but not limited 
to ethnic background, duration of diabetes, uncontrolled diabetes, and hypertension.  A 
recent review article indicated that the highest DR prevalence was in the Western 
Pacific (36%), followed by Africa and the Middle East and North Africa (MENA) 
region each had (33.8%), then Europe with (20.6%) while South East Asia had the 
lowest rate of DR with (12.5%) only (Thomas et al., 2019).  Similarly, A previous meta-
analysis study showed that Caucasians had a much higher rate of DR (46.7%) in 
comparison to Asians, where the prevalence was (20.8%) (Yau et al., 2012). The 
variability in DR prevalence between the different ethnic populations can be due to 
possible genetic susceptibility and socioeconomic differences, including lifestyle, 
nutrition, and the available medical care. Additionally, the 2019 review showed that in 
Europe, the DR occurrence was higher in type 1 diabetic patients, particularly in those 
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over age 30 years, while in Africa, it was much higher in those with type 2 diabetes. 
Likewise, in two other studies, the prevalence of DR was higher in type 1 diabetes 
patients than in type 2 diabetes (Konstantinidis et al., 2017; Nentwich & Ulbig, 2015). 
In contrast, another study found that the DR rate was higher in patients with type 2 
diabetes (Magliah, Bardisi, Al Attah, & Khorsheed, 2018). The conflict of the 
prevalence of DR suggests that the probability of getting DR is due to diabetes and 
glycemic control duration rather than its type. Several studies had shown a significant 
association between increased duration of diabetes and developing DR (Abougalambou 
& Abougalambou, 2015; Bansal, Gupta, & Kotecha, 2013; Magliah et al., 2018; Yau 
et al., 2012). Bansal et al., 2013 reported that having diabetes for more than 15 years 
increases the risk of DR, hence suggesting screening all the patients with diabetes of 10 
years or more for DR regularly (Bansal et al., 2013). Moreover, many studies proved 
that poorer glycemic control and high HbA1c values increase the risk of developing 
DR, whereas proper diabetes control can decrease the DR possibilities (Magliah et al., 
2018; Yau et al., 2012; Yun et al., 2016). Furthermore, like uncontrolled diabetes, high 
blood pressure is shown to increase the risk of developing DR (Magliah et al., 2018; 
Yau et al., 2012). Besides, no significant link was found between DR and sex,  serum 
lipids, and smoking (Magliah et al., 2018). 
Current DR treatment strategies 
The current treatment options of DR include laser photocoagulation, surgical 
interventions (vitrectomy), anti-VEGF drugs, steroids, and peroxisome proliferator-
activated receptor-α (PPAR-α) agonist. Both laser photocoagulation and vitrectomy are 
the earliest to be implemented to treat DR and are used mainly to treat only the disease's 
advanced stages (Sorrentino, Matteini, Bonifazzi, Sebastiani, & Parmeggiani, 2018). In 
laser photocoagulation, the laser is applied into the retina to destroy the newly formed 
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blood vessels and the ischemic tissue to prevent further angiogenesis (Evans, 
Michelessi, & Virgili, 2014). On the other hand, vitrectomy is used to remove vitreous 
hemorrhage, tractional retinal detachment parts, and DME (Heij et al., 2004; Mohamed 
et al., 2007).  However, both procedures are only applied when the retina is already 
damaged and cannot be used as part of the DR preventative approach. In addition, laser 
photocoagulation and vitrectomy can have adverse consequences and may lead to color 
blindness, night blindness, tractional retinal detachment, and hemorrhage (Sorrentino 
et al., 2018).  
Anti-VEGF agents and steroids are used to prevent the development of DR as 
they interfere with the pathogenies process of the disease. As mentioned earlier, the 
overexpression of VEGF stimulates the process of angiogenesis which is the hallmark 
of DR (W. Wang & Lo, 2018). Consequently, the newly formed blood vessels can leak 
and cause vitreous hemorrhage leading to vision impairment (Kollias & Ulbig, 2010; 
Weinreb, Aung, & Medeiros, 2014). However, the anti-VEGF treatment also has 
several challenges. The procedure of administrating the anti-VEGF drug in the eye is 
invasive and requires highly skilled personnel to apply it (Simó & Hernández, 2009). 
Moreover, anti-VEGF treatment is shown to be effective in 50% of patients only (Duh 
et al., 2017). In addition, the anti-VEGF levels should be maintained at the therapeutic 
level necessitating regular intravitreal injection, which can lead to adverse effects such 
as hemorrhage and tractional retinal detachment (Cornel et al., 2015). On the other 
hand, steroids are effective in treating DME. Corticosteroids downregulate ant-
inflammatory mediators and VEGF levels; hence, they improve: 1) blood-retinal barrier 
(BRB), 2) tight junctions between the capillary epithelial cells, and 3) retinal oxygen 
level (Zur, Iglicki, & Loewenstein, 2019). However, the negative impact of using 
steroids is the increased intraocular pressure and cataracts (Barot, Gokulgandhi, Patel, 
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& Mitra, 2013). 
PPAR-α activators are also a potential treatment used to prevent DR. PPAR-α 
agonists such as fenofibrate are reported to increase the expression of apolipoprotein 
A1 (apo-A1) (Simó & Hernández, 2009). It is suggested that Apo-A1 is the major 
transporter of lipids in the retina; therefore, it inhibits lipid accumulations and thus 
lipotoxicity (Simó & Hernández, 2009). Moreover, PPAR-α inhibits the process of 
angiogenesis by downregulating VEGF receptor 2 expression (Meissner et al., 2004).  
Furthermore, PPAR-α is reported to enhance antioxidant enzyme production and 
prevent adhesion molecules' expression on epithelial cells, inhibiting leukostasis and 
inflammation (Bordet et al., 2006; Israelian-Konaraki & Reaven, 2005). 
Pathophysiology 
Several mechanisms and biological processes are involved in DR pathogenesis, 
including oxidative stress, inflammation, and neuroglial alterations. (Roy, Kern, Song, 
& Stuebe, 2017) 
- Oxidative stress and reactive oxygen species  
The role of oxidative stress in diabetic complications of the retinal cells has been 
extensively studied, and significantly increased levels of intracellular reactive oxygen 
species (ROS) have been detected in the retina in studies on diabetes patients and 
diabetic animal models (Whitehead, Wickremasinghe, Osborne, Van Wijngaarden, & 
Martin, 2018). Oxidative stress is induced by several biochemical and molecular 
pathways such as polyol, protein kinase C (PKC), hexosamine, and accumulation of 
advanced glycation end products (AGEs), which causes mitochondrial overproduction 
of ROS (Calderon, Juarez, Hernandez, Punzo, & De la Cruz, 2017). The overload of 
ROS downregulates endogenous antioxidative mechanisms causing oxidizing of 
biomolecules like DNA and proteins, leading to oxidative stress, which in consequence, 
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causes apoptosis of retina cells (Birben, Sahiner, Sackesen, Erzurum, & Kalayci, 2012). 
ROS can directly damage endothelial cells, leading to pro-inflammatory and pro-
constrictive effects (Cristina, Adina, Simona Georgiana, Valerica, & Maria, 2013). In 
addition, as will be discussed in the following section, ROS also has a role in 
inflammation by activating the nuclear factor kappa B (NF-κB) pathway (Jixiang Zhang 
et al., 2016). In normoglycemic conditions, the mitochondrial transcription factor A 
(TFMA) increases the transcription of mitochondrial DNA (mtDNA); however, in 
diabetes, due to hyperglycemia, mitochondrial function is impaired, and TFMA is 
ubiquitylated (Calderon et al., 2017). Consequently, a protein encoded by mtDNA is 
decreased (Santos, Tewari, & Kowluru, 2012), and ROS production is increased, and 
the apoptosis mechanism is activated (Madsen-Bouterse, Mohammad, & Kowluru, 
2010).  
- Inflammation  
Inflammation is well studied to be the etiology of many vascular complications 
of diabetes (Negi, Kumar, Joshi, P K, & Sharma, 2011). Inflammation is the immune 
system response that includes various mediators against invading pathogens (L. Chen 
et al., 2017). These pathogens are recognized by several recognition receptors such as 
Toll-like receptors (TLRs) and AGEs receptors (Sun et al., 2014). When TLRs are 
activated due to stress conditions such as oxidative stress, they activate the production 
of NF-κB, which is a transcription factor. NF-κB increases the transcription of pro-
inflammatory cytokines and chemokines, which recruit and activate leukocytes and 
therefore initiate inflammation (Anne Rübsam, Sonia Parikh, & Patrice E. Fort, 2018). 
Several studies on DR animal models and human patients identified inflammation 
characteristics such as leukostasis, increased cytokines production, increased blood 
flow, vascular hyperpermeability, and edema in the very early stages. One study 
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identified retinal Müller glial cells (MGCs) as the main source of inflammatory 
cytokines and chemokines, which were activated in diabetic patients without clinical 
signs of DR (Vujosevic et al., 2015). MGCs are thought to be responsible for the onset 
of inflammation in DR.   The role of MGCs is supported by the increased levels of 
Intercellular Adhesion Molecule 1 (ICAM-1), an adhesion molecule located on 
endothelial cells, monocyte chemoattractant protein 2 (MCP2), vascular cell adhesion 
molecule 1 (VCAM-1), selectins (E-selectin),  all involved in leukostasis which is 
observed in the early stage of DR (Khalfaoui, Lizard, & Ouertani-Meddeb, 2008; Noda, 
Nakao, Ishida, & Ishibashi, 2012; Vujosevic et al., 2016). Another study performed on 
rats injected with streptozotocin showed increased leukostasis, and interestingly, BRB 
breakdown started after only two weeks of hyperglycemia, indicating the vascular 
hyperpermeability (Rungger-Brändle, Dosso, & Leuenberger, 2000). 
As the disease progress, the elevated systemic expression of pro-inflammatory 
cytokines enhances the angiogenesis process by targeting the endothelial cells (Aplin, 
Gelati, Fogel, Carnevale, & Nicosia, 2006). In a study where human retinal pigment 
epithelial cells and human Müller cells were exposed to hyperglycemic conditions, it 
was demonstrated that endothelial cell injury in diabetes is mostly because of the 
released pro-inflammatory cytokines rather than the elevated glucose (Busik, Mohr, & 
Grant, 2008). In addition, another study reported that the increased release of pro-
inflammatory cytokines leads to the release of adhesion molecules such as ICAM-1, 
which, as mentioned above, causes leukostasis (W. Chen, Esselman, Jump, & Busik, 
2005). As the inflammation progresses, the extravasation leads to the loss of capillary 
pericytes and, consequently, the tight junctions between the endothelial cell break and 
the fluid leaks (A. Rübsam, S. Parikh, & P. E. Fort, 2018). Furthermore, the ischemic 
condition in the retina stimulates the endothelial cells and MGCs to upregulate the 
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production of VEGF, ICAM-1, Monocyte chemoattractant protein-1 (MCP-1), and 
tumor necrosis factor-- α (TNF-α) through hypoxia-inducible factor 1 (HIF-1), which 
is a transcription factor (dell'Omo et al., 2013; Tang & Kern, 2011).   
It is important to highlight the main features of VEGF due to its role in 
inflammation. There are four isoforms of VEGF, which are 121, 165, 189, and 206 
(Park, Keller, & Ferrara, 1993), and only VEGF-165 has been reported to be involved 
in the development of DR (Adamis et al., 1993). VEGF binds to the endothelial cells, 
leading to the activation of membrane tyrosine kinase receptors VEGFR1 (FLT1) and 
VEGF-R2 (FLK1) (Shibuya, 2011). This binding, in turn, activates calcium influx 
channels and MAPK signaling pathways (Shibuya, 2011), leading to 
neovascularization, BRB breakdown, and increases vascular permeability and 
leukostasis, which are the hallmark of DR (Al-Kharashi, 2018). The increased VEGF 
production, MCP-1, and TNF-α increase vascular permeability, which is the case in 
NPDR and DME (Yoshida, Yoshida, & Ishibashi, 2004). In addition, these 
inflammatory cytokines and growth factors enhance neovascularization (angiogenesis), 
which is seen in PDR; thus, inhibiting inflammation, which can interrupt 
neovascularization (Yoshida et al., 2004). In a study on the murine model in which 
ICAM-1 and its cognate receptor CD18 were deleted, deceased neovascularization was 
observed (Sakurai et al., 2003). 
- Adipokines 
Adipokines are hormones and cytokines that are secreted by white adipose 
tissues (Mancuso, 2016). Adipokines include several members performing pro-
inflammatory or anti-inflammatory functions such as TNF-α, Interleukin 6 (IL-6), 
leptin, adiponectin (APN), and Visfatin (Zorena, Jachimowicz-Duda, Ślęzak, 
Robakowska, & Mrugacz, 2020). APN binds to the membrane protein AdipoR1 and 
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AdipoR2, an interaction that increases the activity of PPARα through AMP-activated 
protein kinase (AMPK) phosphorylation (Kim & Park, 2019). The upregulation of 
PPARα, a ligand-activated transcription factor, leads to an increase in fatty acid 
oxidation (Kim & Park, 2019). Moreover, decreased circulating adiponectin levels have 
been associated with insulin resistance in obese diabetes animal models and patients 
(Kwon & Pessin, 2013). 
Adipokines are modulators for several vascular diseases and are suggested to be 
involved in DR pathogenesis (Yilmaz et al., 2004). For instance, TNF-α is a well-
studied pro-inflammatory, and it is involved in inflammation and angiogenesis 
processes. TNFα stimulates the production and transcription of cytokines and vascular 
adhesion molecules, induces BRB breakdown, and is a chemotactic factor for 
neutrophils and monocytes (Zorena et al., 2020). A study on the Asian population 
consisted of 327 diabetic controls without DR, and 158 diabetic patients with DR 
showed that the levels of leptin and adiponectin levels were much higher in DR patients 
(Tan et al., 2014). In another study, significantly higher visfatin levels were detected in 
diabetes patients with PDR than without DR or with NPDR (Y. Wang, Yuan, & Jiang, 
2014). Furthermore, another study results revealed elevated mRNA and protein 
expression of IL-6 in type 2 diabetes patients with PDR (Lu et al., 2017). 
microRNAs 
Overview of miRNA: Function and biogenesis 
miRNAs were first identified in 1993, and its account, along with the other 
ncRNAs, long non-coding RNAs (lncRNAs), and circular RNAs (circRNAs), more 
than 98.5% of the total human genome (C.-H. Liu, Huang, Britton, & Chen, 2020). 
ncRNAs were considered as junk RNAs till recently; they were identified to have a role 
in plentiful various physiological and pathological processes in the human body, 
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making them attractive research interest to understand diseases (Palazzo & Lee, 2015). 
miRNAs are very conserved ncRNAs with a small size of around 22 nucleotide bases 
in length (He & Hannon, 2004). The main function of miRNAs is to regulate 
approximately 60% of the protein-coding gene expression at the post-transcriptional 
level, and therefore it is involved in the different several cellular processes such as 
proliferation, differentiation, and apoptosis (Friedman, Farh, Burge, & Bartel, 2009; 
Osada & Takahashi, 2007). This is done through the complementary binding of 
miRNAs to the 3′-untranslated region (3’UTR) sequence of the messenger RNAs 
(mRNAs) that translate genetic information into proteins and thus terminating its 
translation or degrading it (Krol, Loedige, & Filipowicz, 2010).  
Over the last few years, studies revealed the clinical importance of 
understanding the involvement of thousands of miRNAs in several diseases. 
Interestingly, dysregulation of specific miRNAs in diseases such as cardiovascular 
diseases and various types of cancers has been identified. To name a few, miR-9 and 
miR-21 are downregulated in breast cancer (Singh & Mo, 2013), while miR-1, miR-
145, and miR-499 are decreased in coronary heart disease (Cavarretta & Frati, 2016). 
Additionally, some inherited diseases have been linked to the genetic difference of the 
miRNAs. For example, mutations in miR-17~92 cluster are associated with the growth 
detects (de Pontual et al., 2011). Furthermore, due to their involvement in multiple 
biological processes, miRNAs are considered as clinical biomarkers and therapeutic 
targets for many diseases (Kreth, Hübner, & Hinske, 2018). 
miRNAs biogenesis is initiated in the nucleus of the cells. First, RNA 
polymerase II (Poly II) transcribes miRNA to generate primary miRNA (pri-miRNA), 
forming one or more hairpin loop structures. After that, the Drosha enzyme (RNaseIII 
endonuclease) and its cofactor DiGeorge syndrome critical region 8 (DGCR8) digest 
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the pri-miRNA into shorter precursor miRNA (pre-miRNA), which exportin-5 exports 
to the cytoplasm. Next, the Dicer enzyme (RNaseIII endonuclease) and transactivation 
response element RNA-binding protein (TRBP) will subsequently cleave the pre-
miRNA and remove its terminal loop, yielding a double-strand molecule called miR: 
miR*duplex. Then, the argonaute (AGO) protein interacts with the Dicer enzyme, 
unwinding the double-strand miRNA to a passenger strand, which is degraded, and a 
mature guide strand. Finally, AGO protein interacts with the mature strand and form 
RNA Induced Silencing Complex (RISC) which binds to the targets through binding to 
the complementary sequence of the 3’UTR region of mRNA as mentioned earlier and 
negatively regulate gene expression (Catalanotto, Cogoni, & Zardo, 2016). 
 
 
Figure 1: Biogenesis of miRNA 
 
miRNA and DR 
During the last decade, studies focused on studying changes in miRNAs 
expression in neovascular eye diseases as an approach to use these miRNAs as 
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biomarkers and therapeutic targets. For instance, a study on serum from a patient with 
Age-Related Macular Degeneration (AMD) showed upregulation in the expression of 
miR-146a-5P, miR-126, miR-34a, miR-27a, miR-23a, and miR-9 levels, while it 
revealed a decrease in the expression of miR-155 (Romano et al., 2017). Moreover, in 
a study on premature infants diagnosed with stage 3 Retinopathy of Prematurity (ROP), 
results revealed the upregulation of miR-23a and miR-200b-3p; in contrast, miR-27b-
3p and miR-214-3p were downregulated (Metin et al., 2018). Concerning the role of 
miRNAs in DR, several studies investigated miRNAs' roles in DR in animals, human 
retinal endothelial cells (HRECs), and Retinal Pigment Epithelium (RPE) models and 
humans. These studies revealed changes in the expression of many miRNAs in DR, as 
some were upregulated while others were downregulated (Mastropasqua et al., 2014). 
To understand the function of miRNAs in DR disease development and progression, it 
is important to highlight the role of miRNAs in the inflammation and angiogenesis 
process in general. 
- Role of miRNAs in angiogenesis  
Angiogenesis refers to a regulated process of forming new vessels from pre-
existing vessels through several stimulators and inhibits (Otrock, Mahfouz, Makarem, 
& Shamseddine, 2007). The function of angiogenesis is crucial to maintaining 
physiological homeostasis through the vascular system, which nourishes the tissues and 
organs and eliminates waste (C.-H. Liu et al., 2020). Defects in angiogenesis cause 
interruption in delivering adequate amounts of oxygen and nutrients to the tissues 
leading to improper metabolism (Maier, 2006). Consequently, the affected tissues 
suffer from structural instability and loss of their functions (Maier, 2006). This is 
observed in several diseases with vascular components such as cardiovascular diseases, 
vascular eye diseases, and cancers (Khurana, Simons, Martin John, & Zachary Ian, 
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2005; Usui et al., 2015; Zuazo-Gaztelu & Casanovas, 2018). miRNAs role in 
angiogenesis can be either targeting angiogenesis genes or responding to angiogenic 
factors (Caporali & Emanueli, 2011), and this was observed initially in the mouse 
embryos model.  Mouse embryos with mutation resulting in an insufficient amount of 
Dicer and Drosha enzymes showed defective miRNA biosynthesis, dysregulation of 
angiogenic genes, and defective angiogenesis (Kuehbacher, Urbich, Zeiher Andreas, & 
Dimmeler, 2007; Otsuka et al., 2008; W. Yang et al., 2005). Additionally, these mouse 
embryos' endothelial cells showed a reduction in their angiogenic functions such as 
sprouting, proliferation, migration, and tubulogenesis (Kuehbacher et al., 2007). 
Numerous studies have reported high expression of several miRNAs in human vascular 
endothelium cells and called them angiomiRs due to their association with angiogenesis 
genes (Shusheng Wang & Olson, 2009). A study performed on Streptozotocin (STZ) 
induced diabetic rats discovered that VEGF secretion is controlled by miR-200b 
(McArthur, Feng, Wu, Chen, & Chakrabarti, 2011). Another study on the mice model 
showed that miR-126 enhances the VEGF secretion by suppressing sprouty-related 
protein-1 (SPRED1), which downregulates the VEGF in Ras-MAP kinase pathway, 
hence promoting angiogenesis (Fish et al., 2008). In addition, miR-210 overexpression 
during hypoxic conditions has an important role in cell survival by enhancing 
angiogenesis. One study on human umbilical vein endothelial cells (HUVEC) revealed 
that miR-210 enhances endothelial cell migration and tubulogenesis by targeting 
tyrosine kinase receptor Ephrin A3 (Fasanaro et al., 2008).  Moreover, miR-23 and 
miR-27 of miR-23-27-24 cluster are reported to function as angiogenesis enhancers by 
targeting antiangiogenic proteins Semaphorin 6A (Sema6A) and Sprouty2, which 
inhibits RAF (Zhou et al., 2011), while miR-24 is suggested to suppress cardiac 
angiogenesis, targeting GATA Binding Protein 2 (GATA2), the p21-activated kinase-
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4 (PAK4) (Fiedler et al., 2011). Like miR-24, miR-221/222 has also been recognized 
as angiogenesis inhibit. It functions by blocking c-Kit, a tyrosine kinase receptor of the 
proangiogenic stem cell factor (SCF), thus inhibiting endothelial cell migration and 
tubulogenesis (Song et al., 2017). Likewise, miR-15a and miR-410  are found to 
downregulate VEGF expression in the retinal cells (N. Chen et al., 2014; Q. Wang et 
al., 2016). miR-140 inhibits AGTR1, enhancing the expression of VEGF (Guo, Gu, 
Zhang, Wang, & Gu, 2015). Furthermore, miR-155 is found to downregulate retinal 
neovascularization through regulating the phosphoinositide-3-kinase–protein kinase 
B/Akt (PI3K-PKB/Akt) pathway (Z. Zhuang et al., 2015). Conflict findings were 
reported regarding the role of miR-146 role in angiogenesis. Su et al. conducted a study 
in which they assessed the effect of miR-146 on endothelial progenitor cells in response 
to acute ischemic stroke using a mice model. Their finding revealed that miR-146a/b 
enhanced angiogenesis by targeting TRAF6 and IRAK1 genes (Su et al., 2017). The 
pro-angiogenic role was also supported by a study  that evaluated the impact of miR-
146a on angiogenesis in hepatocellular carcinoma. Zhu et al. found that miR-146a 
inhibits the expression of BRCA1, leading to an increase in platelet-derived growth 
factor receptor α (PDGFRA), which is associated with microvascular invasion (Zhu et 
al., 2013). On the other hand, Knoepp et al. found miR-146a to be anti-angiogenic in 
ischemic myocardium mice (Knoepp et al., 2020). They found that inhibition of miR-
146a significantly enhanced the angiogenesis process. Likewise, in another study, miR-
146a was also reported act as anti-angiogenic through downregulating extracellular 
matrix metalloproteinase inducer (EMMPRIN) which increases VEGF levels in many 
tumors (Amit-Cohen, Rahat, & Rahat, 2013). The effect of the different miRNAs on 




Table 1: Summary of effect of miRNAs on angiogenesis 
 
Effect miRNA Target Reference 
Downregulated miR-200b VEGF (McArthur et al., 2011) 
Upregulated miR-126 SPRED1 (Fish et al., 2008) 














c-Kit (Song et al., 2017) 
Downregulated miR-15a VEGF 
(N. Chen et al., 2014; Q. Wang et 
al., 2016) 
Downregulated miR-410 AGTR1 
(N. Chen et al., 2014; Q. Wang et 








Figure 2: Effect of the different miRNAs on angiogenesis process 
 
- Role of miRNAs in inflammation 
NF-κB is a transcription factor, and as described earlier, it is activated by TLRs 
and induces the production of pro-inflammatory cytokines and chemokines. Apart from 
this, NF-κB activations enhance the transcription of several miRNAs, which are 
released as a feedback response to inflammation (K. Taganov, Boldin, & Baltimore, 
2007). Moreover, adenosine deaminase 1 (ADAR1) and Polyribonucleotide 
Nucleotidyl transferase 1 (PNPT1), which are enzymes involved in RNA metabolism, 
are also reported to influence the production of miRNA (O'Connell, Rao, Chaudhuri, 
& Baltimore, 2010). The feedback function of miRNAs in inflammatory conditions is 
a host protection response. miRNAs prevent the inflammation from becoming chronic, 
hence prevent host damage (Nejad, Stunden, & Gantier, 2018). Some examples of 
miRNAs that are extensively studied in inflammation are miR-146a-5P, miR-155, and 
miR-21. 
miR-146 has two types, miR-146a-5p located on chromosome 5 and miR-146b 
located on chromosome 10. Upregulation of miR-146a-5P/b expression is  NF-κB 
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dependent, and it is promoted by direct binding of NF-κB to its promoter following 
lipopolysaccharide (LPS) stimulation (Ma et al., 2011; K. D. Taganov, Boldin, Chang, 
& Baltimore, 2006). Interestingly, both miR-146a-5p/b, in turn, targets TNF Receptor 
Associated Factor 6 (TRAF6) and Interleukin 1 Receptor Associated Kinase 1 
(IRAK1), which are two major signaling molecules required for activation of NF-κB in 
the TLR/NF-κB pathway (Ma et al., 2011). Moreover, a study using human lung 
fibroblasts cells, in which LPS induced pulmonary injury, reported that miR-146b 
targets MyD88, a signaling mediator, inhibiting NF-κB activation (L. Zhang et al., 
2020). Hence, miR-146a-5p/b functions as a negative feedback regulator of NF-κB. 
Besides that, a study showed that miR-146a-5p has an anti-apoptotic role through 
targeting Fas Associated Death Domain (FADD) (Curtale et al., 2010). The study 
results also revealed lower expression of miR-146a-5p in T naïve cells than T memory 
cells, suggesting a regulatory role of miR-146a-5p in T cell activation by targeting T 
Cell Receptor (TCR) (Curtale et al., 2010). 
miR-155, similarly to miR-146, is also secreted as a feedback response to 
inflammation. However, miR-155 is reported to have both a pro-and anti-inflammatory 
effect (Nejad et al., 2018). There are two mature forms of miR-155: miR-155-3p, which 
is upregulated earlier once stimulated by the TLR/NF-κB pathway, and miR-155- 5p 
that is enhanced later (Mahesh & Biswas, 2019). In addition, a study on human dermal 
lymphatic endothelial cells showed that miR-155 is induced by TNF-α and Interferon-
γ (IFN-γ) (Yee, Shah, Coles, Sharp, & Lagos, 2017). In contrast, the expression of miR-
155 is suppressed by Interleukin-10 (IL-10) to maintain hemostasis (Y. Li & Shi, 2013). 
Interestingly,  miR-155 suppresses the activation of TLRs and the NF-κB pathway by 
targeting several signaling molecules such as TGF-β Activated Kinase 1 Binding 
Protein 2 (TAB2) and MyD88 (Nejad et al., 2018). Moreover, miR-155 downregulates 
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TNF-α and  Interleukin-8 (IL-8) – also known as C-X-C Motif Chemokine Ligand 8 
(CXCL8) (Y. Li & Shi, 2013). Furthermore, miR-155 is reported to inhibit the 
Suppressor of cytokine signaling 1 (SOCS1), which is a negative regulator in the 
JAK/STAT3 pathway and enhances the promoted inflammatory response of 
macrophages (J. Ye et al., 2016). 
miR-21 is expressed widely in many tissues, and it is enhanced by pro-
inflammatory signals produced by various immune cells (Sheedy, 2015). miR-21 has 
been reported to protect the host against inflammation by downregulation of TNF-α 
through silencing phosphatase and tensin homolog (PTEN), Glycogen Synthase Kinase 
3 Beta (GSK3b), and Programmed Cell Death 4 (PDCD4) (Das, Ganesh, Khanna, Sen, 
& Roy, 2014). In contrast, like miR-155, the expression of miR-21 is suppressed by 
Interleukin-10 (IL-10) (Das et al., 2014). Moreover, the upregulated expression of miR-
21 has been detected in cancer and cardiovascular diseases (Kumarswamy, Volkmann, 
& Thum, 2011). Furthermore, a study on lung cancer cell lines showed that miR-21 
could be used as a circulating biomarker and agonist for TLR (Fabbri et al., 2012). 
- Role of miRNAs in DR pathogenesis 
miR‐200b, as mentioned earlier, is inhibiting angiogenesis and endothelial cell 
migration by downregulating VEGF levels (McArthur et al., 2011). In DR, the 
suggested role of miR-200 in the disease pathogenesis is that the hyperglycemic 
condition in diabetes induces dysregulation of miR-200 level. Consequently, VEGF 
expression is increased and thus leads to angiogenesis and disease progression. This 
proposed role of miR-200 in DR pathogenesis is supported by the findings of several 
studies which reported a significant decrease in miR-200 expression in hyperglycemic 
conditions. McArthur et al., 2011 found that diabetic rat retina and epithelial cells 
exposed to high glucose showed decreased expression of miR-200, whereas the level 
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of VEGF was increased (McArthur et al., 2011). Similarly, in another study, the 
hyperglycemic environment's effect on HRECs showed a significant decrease in miR-
200b expression (Qun Jiang, Zhao, Liu, Li, & Liu, 2015). Likewise, significantly 
downregulated expression of miR200b was detected in a study on 255 DR patients 
compared to the healthy controls (E.-H. Li, Huang, Li, Xiang, & Zhang, 2017). 
Moreover, a study on the plasma of type 2 diabetes patients, 91 without DR, 46 with 
NPDR, and 49 with PDR, showed lower miR‐200b in PDR patients than those without 
DR (Dantas da Costa E Silva et al., 2019).  
miR‐29b proposed a role in DR pathogenesis based on its function in regulating 
cell apoptosis and angiogenesis. miR‐29b downregulates Forkhead Box O4 (FOXO4) 
expression, which inhibits cell proliferation and enhances cell death, hence protecting 
MGCs from apoptosis and enhancing eye nerves regeneration (Fu & Tindall, 2008; J. 
Zhang et al., 2018). Additionally, like miR-200b, miR-29b also downregulates VEGF 
expression, thus inhibiting angiogenesis (J. Zhang et al., 2018). Therefore, a reduction 
in miR-29b expression due to high glucose levels can favor DR development. Dantas 
da Costa E Silva et al., 2019 reported elevated VEGF and decreased miR-29b 
expression in PDR patients compared to those with healthy retina (Dantas da Costa E 
Silva et al., 2019). Moreover, J. Zhang et al., 2018 found that when miR-29b was 
downregulated, diabetic rats showed increased expression of FOXO4 and MGCs 
impairment (J. Zhang et al., 2018). In contrast, another study on retinas of STZ induced 
diabetic rats reported upregulated miR-29b and suggested that it may indirectly regulate 
Retina And Anterior Neural Fold Homeobox (RAX) expression and thus preventing 
MGCs apoptosis (Silva et al., 2011). 
miR-146a-5p is reported to have an anti-inflammatory effect through 
downregulating activation of NF-κB by targeting several of its signaling molecules, 
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including IRAK1, TRAF6, and MyD88 (Ma et al., 2011; L. Zhang et al., 2020). In 
addition, miR-146a-5P reduces the expression of adhesion molecule ICAM-1 on 
epithelial cells, hence inhibiting leukostasis (P. Zhuang et al., 2017). Therefore, the 
downregulation of miR-146a-5p plays a potential role in the pathogenesis of DR by 
enhancing inflammation in the vascular system of the retina. Supporting this proposed 
mechanism, several studies conducted on HRECs exposed to hyperglycemic conditions 
showed a steady decrease in the expression of miR-146a-5p (Qiaoyun Gong et al., 2017; 
Q. Wang et al., 2014). Q. Wang et al., 2014 found that with inhibiting miR-146a-5p, 
the expression of IRAK1 and ICAM-1 increased (Qiaoyun Gong et al., 2017; Q. Wang 
et al., 2014). In another interesting study, STZ induced Sprague-Dawley diabetic rats 
were injected with lentivirus after one week of diabetes. The results revealed that miR-
146a-5P expressed by the lentivirus inhibited the upregulation of  NF-κB and ICAM1 
expression, hence, prevented the diabetes-induced retina microvascular defects (P. 
Zhuang et al., 2017). Further, miR-146a is also reported to have an anti-angiogenic role 
through inhabiting IL-6 signaling and consequently suppressing STAT3-VEGF 
pathway (E.-A. Ye & Steinle, 2017a). Figure 3 summarizes the role of miR-146a in DR 





Figure 3 Role of miR-146a in DR. 
 
miRNA-126 role is still under investigation, and different studies have reported 
contradictory roles in angiogenesis and cell invasion. Fang et al., 2017 showed that 
miR-126 inhibits angiogenesis by downregulating VEGF expression through targeting 
Insulin receptor substrate 1 (IRS-1) (Fang, Ma, Guo, & Lu, 2017). They found that 
mimic of miR-126 in epithelial cells downregulated IRS-1 level and consequently 
decreased the release of VEGF (Fang et al., 2017). In contrast, S. Wang et al. concluded 
from their study on miR-126 mutant mice that miR-126 induces angiogenesis by 
enhancing VEGF expression through inhibiting Spred-1, which is an angiogenic inhibit 
(S. Wang et al., 2008). Interestingly in DR, the miR-126 level of expression was found 
to be downregulated. A research study conducted on diabetes mellitus patients, 44 
without DR, 42 with NPDR, and 39 PDR found that the expression level of miR-126 
was downregulated significantly in patients with PDR compared to no DR and NPDR 
groups. (Qin, An, Liu, Xu, & Lu, 2017). Similarly, a study by Rezk et al., 2016 detected 
a significant reduction in miR-126 expression in type 2 diabetes DR (Rezk, Sabbah, & 
Saad, 2016). Overall, downregulation in miR-126 expression is suggested to impact DR 
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development; however, more studies are needed to understand its exact pathogenesis 
mechanism.  
miR-150-5p inhibits angiogenesis, epithelial cell migration, and tubulogenesis 
through downregulating angiogenic genes such as C-X-C Motif Chemokine Receptor 
4 (CXCR4) (C.-H. Liu et al., 2020; Mazzeo et al., 2018). Thus, the downregulated 
expression of miR-150-5p can enhance angiogenesis and lead to the development of 
DR. Mazzeo et al., 2018 study on samples from type 1 diabetes patients, 7 with DR and 
7 without DR showed significantly reduced expression of miR-150-5p in patients with 
DR as compared to those without DR supporting its proposed role in DR pathogenesis 
(Mazzeo et al., 2018).   
Besides the miRNAs mentioned above, the level of several other miRNAs was 
reported to be upregulated in DR. A study performed on type 2 diabetes patients, in 
which 20 without DR, 20 with NPDR, and 20 with PDR using RT-qPCR showed that 
the levels of miR-155 were greater in those with PDR followed by NPDR compared to 
those without DR. The obtained results suggested that miR-155 may be used as a 
biomarker to monitor the progression of the disease (T. T. Yang et al., 2015). Moreover,  
additional studies showed upregulation in the expression of miR-18b, miR19b, miR-
211, and miR-320a in type 1 diabetes patients with DR, while expression of miR-21, 
miR-181c and miR-1179 was found to be higher in type 2 diabetes patients with DR 
(Qi Jiang, Lyu, Yuan, & Wang, 2017; Y. Liu et al., 2017; Qing et al., 2014; Zampetaki 
et al., 2016; Zou, Wang, Gang, Zhang, & Sun, 2017). 
Among the above-mentioned miRNAs, miR-146a-5p is largely and well-
identified to have an anti-inflammatory effect. Because miR-146a-5p was reported in a 
previous study by Al-Sadeq, 2018 to be upregulated by adiponectin treatment in HRECs 
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CHAPTER 3: RESEARCH QUESTION AND HYPOTHESIS 
DR is a complication of diabetes disease, and many different mechanisms cause 
it. In hyperglycemic conditions, both adiponectin and hsa-mir-146 5p are 
downregulated. A previous study showed that treating HERCS exposed to diabetic 
conditions with adiponectin increases miR-146a-5P expression (Al-Sadeq, 2018); this 
finding suggested that adiponectin actions are potentially mediated through miR-146a-
5P. Both adiponectin and hsa-mir-146 5p target and regulate NF-κB, TNF-α, and 
ICAM-1 expression.  
Therefore, in the current research study, we hypothesize that miR-146a-5p may 
ameliorate the inflammation in HRECs via the peroxisome proliferator-activated 
receptor-α signaling pathway (PPAR-α) and its target molecules, which is involved in 
the genesis of early changes in HRECs when exposed to hyperglycemic conditions 
mimicking the adiponectin effect. 
Therefore, this study aims to extend the previous work to explore the impact of 
hsa-mir-146-5p on diabetic milieu and to highlight the impact of using miR-146a-5p to 
mimic adiponectin actions, especially in diabetic subjects who are characterized by low 
adiponectin levels.  
To achieve the aim, the objectives of this study are to examine and assess the 
effect of hsa-miR-146a-5p in HRECs exposed to high glucose on:  
- The total cellular ROS production and oxidative stress status 
-  Rate of apoptosis 
- The expression of PPARα, inflammatory/apoptotic biomarker TNF-α, 




- Profiling of genes involved in inflammation and angiogenesis to determine 
the molecular pathways  
- Gathering data of the current study will reveal the role of hsa-miR-146a-5p 




CHAPTER 4: MATERIALS AND METHODS 
Biosafety approval 
The Qatar university institutional Bio-safety committee has approved the 
present study# QU-IBC-2020/077 (See Appendix). 
Reagents and instruments: 
Reagents and instruments used in the study for the different experiments and 
assays are listed in Table 2. 
 




Human Retinal Microvascular Endothelial 












Complete Medium Formulated at Normal 





























D-Glucose Sigma-Aldrich G-7021 
D-Mannitol Sigma-Aldrich M4125 
Phosphate Buffered Saline (PBS) Tablets Gibco 18912-014 
0.05% Trypsin-EDTA (1X) Gibco 25300-054 
Gibco™ Opti-MEM™ I Reduced Serum 
Medium 
Gibco 31985070 
mirVana hsa-miR-146a-5p ID:MC10722 
miRNA mimic 
Ambion 4464066 
mirVana hsa-miRNA mimic Negative 
Control #1 
Ambion 4464058 
mirVana hsa-miR-146a-5p ID:MH10722 
miRNA inhibit 
Ambion 4464084 
Anti-miR Negative Control #1 Ambion AM17010 
Lipofectamine RNAiMAX Invitrogen LMRNA015 
HUMAN TNF-- Α 50 UG BIOSOURCE  Invitrogen PHC3016 
QIAzol Lysis Reagent Qiagen 79306 
Chloroform Sigma-Aldrich 650498 
Ethanol  Sigma-Aldrich 32221 






Qubit™ Assay Tubes Invitrogen Q32856 













TaqMan® Gene Expression Assay 



















TaqMan® Gene Expression Assay 














CellROX™ Orange Reagent Invitrogen C10443 
Tali® Cellular Analysis Slides Invitrogen T10794 









The different treatment and transfection groups and downstream experiments 
are illustrated in Figure 4. 
 
Instrument Company 
Thermocycler (Gene Amp®, PCR System 
9700)  
Applied Biosystem 
7500 Real-time PCR system  Applied Biosystem 
Tali™ Image-Based Cytometer  Invitrogen 
Qubit® 4.0 Fluorometer Invitrogen 
Nanodrop™ Lite Spectrophotometer Thermo Scientific 
EVOS XL Core Imaging System  Invitrogen 









Human Retinal Endothelial Cells (HRECs) culture and passage 
First, a T75 flask was prepared using 5ml of attachment factor to cover the 
surface and then was removed and returned to the original bottle to reuse. In addition, 
15ml of complete classic media (with culture boost and Bac-off) was warmed to 37°C. 
Then a vial with 1ml of cryopreserved passage 5 (P5) HRECs was warmed and thawed 
in hands, then immediately in ambient temperature, complete classic media was added. 
Thawed cells were added to the prepared flask, and then 15ml of warmed complete 
classic media was added. Flask was moved flask in (east-west, north-south) motion to 
ensure even spread of cells over flask surface and then the flask was incubated in 5% 
CO2 incubator at 37°C until 80% - 90% confluency. After 48 hours of growth, the 
complete classic media was changed. Upon confluency, cells were passaged to P6, 
which were then seeded and used in the study.  
Before seeding, HRECs were counted using Trypan blue. In a well, 20μl of 
Trypan blue and 20μl of cell suspension were mixed, then 20μl of the mixture was 
loaded on a hemocytometer and was viewed under an inverted microscope. The cell 
number counted in two corner squares and the middle square were used in the following 
formula to retrieve the total cells number:  
[Total number of cells counted / (No. of squares)] × 2(dilution factor) × 10,000 
In this study, three P5 HRECs vials were used, which represented three different 
biological samples. 
HRECs treatment 
A total of 1 x 105 of P6 HRECs were seeded per well on 24 well plates 
according to the number of conditions and experiments for 96 hours for chronic 
treatment using three different treatment media: Normal Glucose (NG) using complete 
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media with 5 mM glucose (4N0-500-R), High Glucose (HG) where D-glucose powder 
was added to complete media with 5 mM glucose (4N0-500-R) to reach a final 
concentration of 25mM, and osmotic control Mannitol (M), where D-mannitol powder 
was added to complete media with 5 mM glucose (4N0-500-R) to reach a final 
concentration of 25mM. Then the plates were incubated in 5% CO2 incubator at 37°C. 
HRECs transfection 
In this study, we studied the effect of two concentrations of miR-146a-5p. For 
low dose study: miR-146a-5p transfection, miR-146a-5p mimic, miR-146a-5p inhibit, 
and the scramble sequences were used at a concentration of 10 nM, while for high dose 
study;  miR-146a-5P-5p mimic and the scramble sequence were used at a concentration 
of 50 nM. The procedures in brief, after 48 hours of treatment with various glucose 
concentrations, and with ~80% confluency (cell count: 24 well plate = 0.5–2 × 105; 6 
well plate= 0.25-1 × 106), the treatment media were replaced with serum-free media for 
6 hours to serum starve the HRECs. Then, the serum-free media was removed, and cells 
were divided into three groups for transfection for 48 hours in 5% CO2 incubator at 
37°C.  
Group (A) non-transfected group: contained four control samples with treatment 
media as mentioned above:  
1) NG,  
2) NG+TNF-α 
3) HG 
4) M as osmotic control 
Group (B) overexpression of miRNA-146a-5p: as a mimic group contained four 
samples/ treatment:  
1) miR-146a-5p mimic in NG media  
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2) miR-146a-5p mimic in HG media  
3) mimic negative control in HG media  
4) miR-146a-5p mimic+ TNF-α 
Group (C) knockout or silencing group of miRNA-146a-5p: as inhibitory group 
contained two samples/ treatment:  
1) miR-146a-5p inhibitory in HG media, and  
2) Scrambled inhibitory negative control both in HG media.  
Upon completion of 48 hours incubation, TNF-α at 1ng/ml was added to the specific 
wells and incubated for additional 4 hours. 
 
Table 3: Groups treatment and duration. L: Low dose (10 nM); H: High dose (50 nM) 
Group Treatment Incubation duration 
NG Normal glucose (5 mM) 96 hours 
NG + miR-146a-
5p mimic (L) 
Normal glucose (5 mM) + 10 
nM miR-146a-5p mimic 
96 hours treatment + 48 
hours transfection 
NG + TNF - α 
Normal glucose (5 mM) + 
1ng/ml TNF-α 
96 hours treatment + 4 hours 
TNF - α treatment 
NG + miR-146a-
5p mimic + TNF-α 
(L) 
Normal glucose (5 mM) + 10 
nM miR-146a-5p mimic + 
1ng/ml TNF-α 
96 hours treatment + 48 
hours transfection + 4 hours 
TNF - α treatment 
HG High glucose (25 mM) 96 hours 
HG + miR-146a-
5p mimic (L) 
High glucose (25 mM) + 10 
nM miR-146a-5p mimic 
96 hours treatment + 48 
hours transfection 
HG + miR-146a-
5p inhibit (L) 
High glucose (25 mM) + 10 
nM miR-146a-5p inhibit 
96 hours treatment + 48 
hours transfection 
HG + scramble 
sequences (L) 
High glucose (25 mM) + 10 
nM scramble sequences 




Group Treatment Incubation duration 
NG + miR-146a-
5p mimic (H) 
Normal glucose (5 mM) + 50 
nM miR-146a-5p mimic 
96 hours treatment + 48 
hours transfection 
HG + miR-146a-
5p mimic (H) 
High glucose (25 mM) + 50 
nM miR-146a-5p mimic 
96 hours treatment + 48 
hours transfection 
HG + scramble 
sequences (H) 
High glucose (25 mM) + 50 
nM scramble sequences 
96 hours treatment + 48 
hours transfection 
 
• miR-146a-5p inhibit: A single oligonucleotides strand that binds to mature 
miR-146a-5p to knock it out. 
• miR-146a-5p mimic: A double stand RNA that, when introduced to the cell, it 
increases the expression of miR-146a-5p and mimics its function. 
• Scramble sequence: A stand with similar size of mimic and inhibit stands; 
however, it consists of a randomly arranged (ACGT) sequence. 
• Lipofectamine® RNAiMAX: A lipid media formulation that is used to 
transfect siRNA and miRNA into the cell. 
Cell growth parameters 
- Apoptosis and viability  
Trypsinized HRECs were washed using 1ml classic complete media, 
centrifuged at 500x g for 5 minutes, and the supernatant was discarded. The cell pellet 
was then resuspended in 100µl, to which 100µl of Annexin V & Dead Cell Kit 
(MCH100105) and then incubated for 20 minutes in the dark. Following that, tubes 
were analyzed on Muse™ Cell Analyzer using NG sample as the control. 
- ROS production 
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Trypsinized HRECs were washed using 1ml classic complete media, 
centrifuged at 500x g for 5 minutes, the supernatant was discarded, and then cells were 
resuspended in 2ml of media. Two microcentrifuge tubes were retrieved for each 
sample, one labelled as stained and the other as unstained, and 1ml of cell suspension 
was added to each tube. Then, CellROX™ Orange Reagent was used to measure ROS 
production in live cells. In brief, 2 L of the reagent was added to cells in a tube labelled 
as stained, mixed with a pipette, and both tubes were incubated at 37°C for 30 minutes 
in the dark. After that, tubes were centrifuged, and the supernatant was discarded. Next, 
cells were washed by adding 1ml PBS, mixing, and centrifugation, for a total of three 
times. Finally, cells were resuspended with 1 mL PBS and 25 L were loaded on Tali 
slide. The samples were analyzed on Tali following the instrument instructions with 
using the unstained sample as the reference. 
Genes expression 
RNA extraction:  
Briefly, culture media was removed from the wells, then 400µl of QIAzol lysis 
reagent was added to each well to homogenize the cells. Using a scraper, cells were 
detached and then were collected in microcentrifuge tubes. After that, 200μl of 
chloroform was added to each tube, shaken for 10 seconds vigorously, and incubated 
at room temperature for 3 minutes. Following incubation, tubes were centrifuged for 15 
minutes at 12000xg and 4oC. Next, inside a clean hood, the clear upper aqueous layer 
~ about 200µl (containing RNA) was carefully collected and transferred to new 
microcentrifuge tubes. Then, to precipitate the RNA, 500µl of isopropanol was added 
to each tube, mixed by inverting, and incubated at room temperature for 10 minutes. 
Following incubation, tubes were centrifuged for 10 minutes at 12000xg and 4oC. 
Afterward, the liquid layer was carefully removed and discarded without touting the 
 
39 
white RNA pellet in the bottom of the tube. After that, the pellet was washed with 500μl 
of 75% ethanol, centrifuged for 5 minutes at 7500xg and 4oC. The liquid layer was 
carefully removed and discarded, and the pellet was air-dried for 5-10 minutes. Finally, 
20μl of nuclease-free water was added to the pellet, mixed by pipetting up and down 
gently, and immediately tubes were kept on ice for immediate use in downstream 
applications or stored at -80oC until used for further analysis. 
Total RNA concentration, integrity, and quality 
Total RNA concentration of samples was measured using the Nanodrop Lite 
instrument, and 260/280 ratio >1.8 was used to assess the purity. After that, to measure 
the total RNA's integrity and quality, RNA IQ Assay Kit was used following the 
manufacturer's instructions, and the samples were analyzed on Qubit® 4.0 Fluorometer. 
RNA integrity number (RIN) >8 was considered acceptable for miRNA and gene 
expression assays. Examples of RNA purity and integrity data are shown in a Table in 
the appendix  
cDNA preparation 
- cDNA from RNA 
cDNA was synthesized from mRNA using the High Capacity RNA to cDNA 
reverse transcription kit following the manufacture instructions. In brief, for each 
sample, a reaction mixture was prepared (total volume = 20µl) by mixing the indicated 
volumes of following components in order:  10μl of 2X RT Buffer Mix, 1 μl of 20X 
RT Enzyme Mix, up to 9μl RNA sample (up to 2 μg in 20μL reaction) and nuclease-
free water to complete quantity to 20μl. Then, tubes were briefly mixed, centrifuged, 
and placed in a Gene Amp thermocycler to perform reverse transcription by incubating 
at 37oC for 60 minutes, followed by reaction stopping at 95oC for 60 minutes and 
finally holding at 4oC.  
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- cDNA from miRNA 
miRNA was converted to cDNA using the TaqMan® Advanced miRNA Assays 
reverse transcription kit following the manufacturer's instructions. The process of 
synthesizing cDNA is performed in 4 stages. In the first stage, the mature transcript is 
extended by adding poly(A) to the 3' end. Then the 5’ is elongated. After that, reverse 
transcription is performed, followed by a miR-Amp reaction to increasing the quantity 
of cDNA. The resulted product is then used as the template for RT-PCR assay. Detailed 
component volumes and thermocycler programs are indicated in manufacturer protocol. 
Quantitative Real-time PCR 
Quantitative RT-PCR was performed using TaqMan® Fast Advanced Master 
Mix and the specific primers set on 7500 Real-time PCR system. In brief, for each gene, 
4μL of cDNA was pipetted in the bottom in 96 well PCR plate, then reaction master 
mix was prepared for each gene by mixing the volumes of specific Primer sequence, 
Fast Advanced Master Mix and RNase-free water as shown in Table 4. After that total 
of 16μL of reaction master mix was added to each well-containing DNA sample for a 
total volume of 20μL. Finally, the plate was mixed, centrifuged, and processed on 7500 
Real-time PCR system. 
 
Table 4: Components and primers sequences used for genes and miRNA expression 
Genes expression 
Reagent Volume per reaction (ul) 
TaqMan® Gene Expression Assay 1 
TaqMan® Fast Advanced Master Mix 10 
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Reagent Volume per reaction (ul) 
cDNA template 4 
RNase-free water 5 
Total volume 20 
Primers 












Reagent Volume per reaction (ul) 
TaqMan® Fast Advanced Master Mix  10 
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Reagent Volume per reaction (ul) 
TaqMan® Advanced miRNA Assay (20X) 1 
Diluted cDNA 5 
RNase-free water 4 






- Optimization of seeding density 
The current study includes treating HRECs with different media (NG, HG, and 
classic complete media) for 96 hours followed by 48 hours of transfection incubation, 
thus optimizing the initial cell count to be used for seeding to avoid over confluency 
during incubation days was important. 
A T75 flask with confluent HRECs and 6 wells plates were obtained, and cells 
were seeded with three different cell counts 5 x 104, 1 x 105, and 2 x 105  and the three 
different media that will be used in the experiment as shown in the below Figure 5, and 





Figure 5: Seeding optimization experiment plate layout 
 
After that, the wells were examined using EVOS XL Core Imaging System, and 
wells seeded with 5 x 104 were confluent and viable in all three media, while the wells 
with 1 x 105 and 2 x 105 counts had a large percentage of floating cells as shown in 
Figure 6, thus seeded with 5 x 104 was selected to start seeding with. 
 
 
Figure 6: Seeding optimization experiment results. Microscopic images of the different 
seeding count of HRECs by the end of 96 hours incubation.  
 
- Assessing transfection efficacy 
Since transfection is the main point in the entire study and all the outcomes 
depend on it, assessing the efficacy of transfection is essential. In brief, HRECs P5 were 
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cultured in a T75 flask for 2 days in a complete culture media, then sub-cultured for 2 
days in two T75 flasks. After that, cells were seeded in a 6 wells plate and was incubated 
in 5% CO2 incubator at 37°C until ~80% confluency. Then transfection with miR-146a-
5p mimic (double-stranded RNA molecules), miR-146a-5p inhibit (single-stranded 
oligonucleotides), and negative control for mimic and inhibit miR-146a-5p (scramble 
sequence) were performed using Lipofectamine according to the manufacturer 
instructions, and the plate was incubated for 48 hours in 5% CO2 incubator at 37°C. 
Then total RNA was extracted, and the expression of miR-146a-5p was measured using 
RT-PCR. 
RT2 Profiler PCR Arrays (Inflammatory and Angiogenesis) 
Two RT² Profiler PCR Arrays, Human Inflammatory cytokines, and receptors 
array (PAHS-011ZA-12) and Human Angiogenesis array (PAHS-024ZA-12), were 
used to assess the inflammatory cytokines and angiogenesis genes in HRECs exposed 
to hyperglycemia and transfected with 50nM miR-146a-5p. An array of each profile 
comes in a 96 well format that includes preloaded primers of specific 84 genes 
(cytokines, receptors, chemokines, adhesion molecules, inhibitors, etc.) depending on 
the type of array, in addition to primers for negative and endogenous controls. See 
Appendix C and Appendix D for a list of genes included in each array. In brief, a master 
mix was prepared by combining 1350 ul of 2x RT2 SYBR Green Master  Mix, 102 ul 
of cDNA, and 1248 ul of RNase-free water. Then 25 ul were loaded per well, and the 
plate was mixed, centrifuged, and processed on 7500 Real-time PCR system. 
Differentially expressed genes (Group et al.) were generated using Gene Globe analysis 
software available on the Qiagen website. The threshold for significance in expression 
change was set at FC of ≤ -1.4 for downregulated and upregulated genes. Also, the 
Student’s t-test of the replicate 2(-Delta CT) values for each gene in the control group 
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and treatment groups were determined using Gene Globe analysis from Qiagen.  The 
options selected on Gene Globe were as the following: based on the type of the array, 
inflammatory or angiogenesis, the correct catalogue was selected. Then, CT value was 
set to 35, the fold regulation was set to  2, and P-value to 0.05. Normalization was done 
based on the geometric mean of five housekeeping genes: Actin-beta, B2M, GAPDH, 
HPRT1, RPLPO. 
Bioinformatic Analysis 
To determine the biological significance and functional classification of the 
genes, we performed bioinformatic analysis using the Metscape enrichment pathways 
analysis tool (metascape.org) and Ingenuity Pathway Analysis (IPA) software. 
Statistical Analysis 
Three biological replicates and 3-9 technical replicates were performed for each 
sample and experiment; hence, data are presented as mean with standard deviation. 
Statistical significance was determined by comparing the different treatment groups to 
the NG as the control followed by sub-comparisons between the different groups as 
specified using one-way ANOVA and Student T-test through GraphPad prism 9 or 




CHAPTER 5: RESULTS 
A - Effect to a low dose (10 nM) of both miR-146a-5p mimic and inhibit 
Apoptosis and viability 
The apoptosis percentages (sum of early and late phases) obtained by Annexin 
V & Dead Cell Kit on Muse cell analyzer showed no significant difference in apoptosis 
percentage of HG-treated HRECs when compared with NG treated cells. In addition, 
transfection with miR-146a-5p mimic in normoglycemic did not significantly affect the 
apoptosis percentage compared to NG sample. Moreover, miR-146a-5p mimic and 
inhibit transfection in hyperglycemic did not significantly affect the apoptosis rate. In 
fact, all the HRECs samples showed similar apoptosis percentages to the NG sample, 
as shown in Figure 7a, b. Then we compared the percentage of live and dead cells 
percentages between the samples. Hyperglycemia did not affect the percentage of live 
and dead cells in comparison to the normoglycemia condition. Furthermore, we 
compared the impact of transfecting 10nM miR-146a-5p mimic and inhibitor in 
samples exposed to hyperglycemia in terms of live and dead percentages.  Percentage 
of live and dead cells was not affected by neither miR-146a-5p mimic nor miR-146a-



























































































Figure 7: Live, dead, and Apoptosis data (a) Flow cytometry images obtained by Muse 
cell analyzer shows the percentage of live, dead, early, and late apoptotic cells in the 
different samples used in the study (b) Quantitative representation of total apoptosis 
(early and late) percentages of the samples used in the study (c) Quantitative 
representation of live and dead cells percentages of the samples used in the study. NG: 
Normal glucose; HG: High Glucose. All data in the graph present a mean and standard 
deviation of n=9 for each sample. miR-146a-5p mimic and inhibitory concentration= 
10nM. ns: not significant. Two tailed p value is significant ≤ 0.05. 
 
ROS production 
ROS production in HRECs exposed to the different treatment and transfection 
conditions was assessed using CellROX™ Orange Reagent and analyzed on Tali 
analyzer. Our results showed that ROS production was significantly increased in 
HRECs exposed to chronic hyperglycemia compared to the normoglycemic control, as 
shown in Figure 8.  
Then, the production of ROS was assessed in the samples with miR-146a-5p 
overexpressed using 10nM mimic, along with using scramble sequence as a negative 
control. As expected, the scramble sequence did not affect the ROS production; 




increased the ROS production compared to hyperglycemia control Figure 8. Following 
that, the impact of miR-146a-5p knockout on ROS production was assessed. In line 
with the published literature, knocking out miR-146a-5p significantly increased ROS 
production compared to hyperglycemia control, Figure 8. Moreover, a comparison of 
ROS production rate between overexpressing miR-146a-5p with 10nM and knocking it 
out was performed. The data showed that knocking out miR-146a-5p significantly 
increased ROS production compared to overexpressing using 10nM mimic, Figure 9. 
Further, because of the unexpected effect of overexpressing miR-146a-5p with 10nM 
dose, its effect in normoglycemic condition was assessed. Interestingly, findings 
showed that 10nM miR-146a-5p significantly elevated ROS production compared to 





















































































Figure 8: Comparison of ROS production between NG control and all the samples. 
Quantitative representation of ROS production in all samples used in the study 
compared to NG as control. NG: Normal glucose; HG: High Glucose. All data in the 
graph are presented as bars with a mean and standard deviation of n=9 for each sample. 
miR-146a-5p mimic and inhibitory concentration used is 10nM. ns: not significant; 





Figure 9: Comparison of ROS production between HG sample and the samples 
transfected with miR-146a-5p mimic and inhibit. Quantitative representation of ROS 
production in miR-146a-5p mimic and inhibit samples in comparison to HG treated 
sample. HG: High Glucose. All data in the graph are presented as a mean and standard 
deviation of n=9 for each sample. miR-146a-5p mimic and inhibitory concentration 
used is 10nM. **** indicates P ≤ 0.0001. Two tailed p value is significant ≤0.05. 
 
miR-146a-5p expression 
This experiment was performed to identify the impact of hyperglycemia and 
transfection with 10 nM miR-146a-5p mimic and inhibitor on miR-146a-5p expression. 
Expression during optimization 
As shown in Figure 10, the CT values and expression of miR-146a-5p were 
significantly increased with miR-146a-5p mimic transfection by 18-folds, while miR-
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146a-5p inhibit significantly decreased the miR-146a-5p expression by 500-folds 
compared to the negative control (scrambled sequence). 
 
 
Figure 10: Assessing transfection efficacy. Quantitative representation of CT values. 
All data in the graph present a mean of n=4 for each sample. miR-320a was used as 
endogenous control. miR-146a-5p mimic and inhibitory concentration used is 10nM. * 
indicates value significantly different than the control group. Two tailed p value is 
significant ≤0.05. 
 
Expression during transfection with 10nM  
First, the effect of normoglycemia and hyperglycemia treatments were 
compared. Chronic hyperglycemia exposure caused a significant change in miR-146a-
5p expression, decreasing it by 7 folds compared to the normoglycemia control, Figure 
11 a. Then the expression of miR-146a-5p using 10nM miR-146a-5p mimic, along with 
using the scramble sequence as a negative transfection control was assessed.  Data 
showed that transfection with 10nM miR-146a-5p mimic significantly increased the 
expression by 302 folds, while the scrambled sequence did not affect Figure 11 b. 
Further, miR-146a-5p expression post-miR-146a-5p inhibitor transfection, along with 
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using the scramble sequence as negative transfection control, was assessed.  Findings 
showed that transfection with miR-146a-5p inhibitory significantly decreased the 
expression of miR-146a-5p by 7 folds while the scrambled sequence did not have any 
effect, Figure 11 c. Together, these results demonstrate that transfection with both miR-








Figure 11: Quantitative representation of fold change in miR-146a-5p expression (a) 
Comparison of miR-146a-5p expression between NG and HG. (b) Comparison of miR-
146a-5p expression between HG, HG+ 10 nM miR-14a-5p mimic and scramble 
sequence (c) HG+ 10 nM miR-14a-5p inhibit and scramble sequence. NG: Normal 
Glucose; HG: High Glucose; NC: Negative Control (scramble sequences). All data in 
the graph are presented as the mean of n=4 for each sample. miR-320a was used as 
endogenous control. miR-146a-5p mimic and inhibitory concentration used is 10nM. * 




The expression of four genes was tested TNF - α, ICAM 1, PPAR–α, and 
TRAF6, the main target gene of miR-146a-5P. TRAF6 expression was not changed 
significantly in any of the samples compared to NG or to the other samples; hence, the 
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below lines highlight the effect on TNF - α, PPAR–α, and ICAM 1. 
First, assessing the effect of transfecting with 10 nM miR-146a-5p mimic under 
normoglycemic condition. This experiment aimed to identify the effect of 10 nM miR-
146a-5p on gene expression in normoglycemic conditions. Our results showed an 
unexpected significant increase in TNF - α expression with 59998-fold, ICAM 1 with 
48-folds, and PPAR- α around 3-folds compared to the NG sample Figure 12. These 
data indicated that overexpression of miR-146a-5p with a low dose could have a pro-
inflammatory and pre-apoptotic effect, which affects the biological function of the cells 
adversely to the well-established functions of the studied genes. 
 
Figure 12: Expression genes in NG and NG+miR-146a-5p mimic. Comparison of TNF 
– α, PPAR – α, ICAM1, and TRAF 6 expression between NG and NG+miR-146a-5p 
mimic NG: Normal Glucose. All data in the graph are presented as the mean of n=4 for 
each sample. Beta-actin (ACTB) is used as endogenous control. miR-146a-5p mimic 
concentration= 10nM. TNF - α protein concentration used is 1ng/ml * indicates P ≤ 
0.05. Two tailed p value is significant ≤0.05. 
 
In addition, we assessed the effect of treating samples exposed to 
normoglycemia condition with TNF - α protein at 1ng/ml for 4 hours. This experiment 
aimed to identify the effect of TNF-α which is a well-known pro-inflammatory and pro-
apoptotic cytokine on HRECs on gene expression in normoglycemic conditions to 
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mimic inflammatory conditions observed in hyperglycemic conditions. We found that 
treatment with TNF – α protein significantly increased TNF-α expression by 6129-folds 
and ICAM1 by a 68-fold expression, whereas the expression of PPAR-α was not 
significantly affected as shown in Figure 13a, b. The results indicated that treatment 
with TNF-α could be pro-inflammatory and pre-apoptotic in terms of increasing 
expression of ICAM1.  Interestingly, the expression of TNF–α was even greater with 
transfection with miR-146a-5p in the presence of TNF - α in the normoglycemic 






Figure 13: Expression of PPAR- , ICAM-1, and TRAF6 genes in NG and NG+TNF – 
α (a) Comparison of TNF–α expression between NG and  NG+ TNF – α (b) Comparison 
of PPAR – α, ICAM1 and TRAF 6 between NG, and NG+TNF- α. NG: Normal 
Glucose. All data in the graph represent the mean of n= 4 for each sample. Beta-actin 
(ACTB) is used as endogenous control. TNF-α protein concentration used is 1ng/ml. * 
indicates a significant difference between NG+TNF versus NG, P ≤ 0.05. Two tailed p 




Figure 14: Expression of TNF - α in NG and NG+TNF - α+ miR-146a-5p mimic. NG: 
Normal Glucose. All data in the graph represent the mean of n= 4 for each sample. 
Beta-actin (ACTB) is used as endogenous control. miR-146a-5p mimic concentration 
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used is 10nM. TNF - α protein concentration used is 1ng/ml * indicates a significant 
difference between NG and NG+TNF - α+ miR-146a-5p mimic, P ≤ 0.05. Two tailed 
p value is significant ≤0.05. 
 
Hence, we compared the gene expression in the normoglycemic sample treated 
with TNF - α at 1ng/mL for 4 hours with and without miR-146a-5p mimic to assess the 
impact of miR-146a-5p mimic on inflammation. Surprisingly, the result showed that 10 
nM of miR-146a-5p mimic increased TNF-α expression significantly by almost 9-folds 
compared to only TNF–α treatment. The expression of PPAR-α and ICAM 1 were not 
affected, Figure 15. Further, interestingly, when the expression of the three genes was 
compared between normoglycemic samples with only 10 nM miR-146a-5p mimic or 
TNF - α at 1ng/mL for 4 hours, the miR-146a-5p mimic showed a significant increase 
in TNF - α expression almost 10-folds and PPAR–α by 2-folds in comparison to TNF - 
α treatment, Figure 16. 
 
 
Figure 15: Expression of TNF - α, PPAR–α, ICAM1 in NG+TNF - α and NG+TNF - 
α+ miR-146a-5p mimic. NG: Normal Glucose. All data in the graph represent the mean 
of n= 4 for each sample. Beta-actin (ACTB) is used as endogenous control. miR-146a-
5p mimic concentration used is 10nM. TNF - α protein concentration used is 1ng/ml * 
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indicates a significant difference between NG and NG+TNF - α+ miR-146a-5p mimic, 
P ≤ 0.05. Two tailed p value is significant ≤0.05. 
 
 
Figure 16: Expression of TNF - α, PPAR–α, ICAM1 in NG+TNF - α Vs. NG + miR-
146a-5p mimic. NG: Normal Glucose. All data in the graph represent the mean of n= 4 
for each sample. Beta-actin (ACTB) is used as endogenous control. miR-146a-5p 
mimic concentration= 10nM. TNF - α protein concentration= 1ng/ml. * indicates a 
significant difference between NG+ TNF alpha and NG+ miR-146a-5p mimic, P ≤ 
0.05. Two tailed p value is significant ≤0.05. 
 
On the other hand, a comparison of gene expression in the normoglycemic 
condition with transfection of miR-146a-5p mimic with and without TNF - α treatment 





Figure 17: Expression of TNF - α, PPAR–α, ICAM1 in NG+TNF - α+miR-146a-5P 
and NG + miR-146a-5P mimic. NG: Normal Glucose. All data in the graph represent 
the mean of n= 4 for each sample. Beta-actin (ACTB) is used as endogenous control. 
miR-146a-5p mimic concentration used is 10nM. TNF - α protein concentration used 
is 1ng/ml. Two tailed p value is significant ≤0.05. 
 
After that, we assessed the gene expression between normoglycemic and 
hyperglycemic conditions. We found that exposure to hyperglycemia significantly 
increased the expression of TNF – α, ICAM1, and TRAF-6 by 20-folds, 25-folds, and 





Figure 18 Expression of TNF – α, PPAR–α, ICAM1, TRAF-6 in NG and HG. NG: 
Normal Glucose; HG: High Glucose. All data in the graph represent the mean of n= 4 
for each sample. Beta-actin (ACTB) is used as endogenous control. * indicates the 
significant differences of gene expression of TNF – α, PPAR–α, TRAF-6 in HG vs. 
NG.  Two tailed p value is significant ≤0.05. 
 
Surprisingly, when the hyperglycemic sample was transfected with miR-146a-
5p mimic, TNF - α expression, PPAR–α, and ICAM1 increased significantly by 38404-
folds, 1.48 -folds 43.5-folds, respectively, in comparison to the normoglycemic sample 
Figure 19a, b. Similarly, the expression of TNF - α, PPAR–α, and ICAM1 was also 
increased significantly when the hyperglycemic sample was transfected with miR-
146a-5p inhibit by 30842-folds, 1.5-folds, and 33-folds, respectively, in comparison to 





Figure 19 Expression of genes in NG and HG+miR-146a-5p mimic (a) Comparison of 
TNF – α expression between NG and HG+miR-146a-5p mimic (b) Comparison  
PPAR–α, ICAM1 and TRAF 6 expression between NG and HG+miR-146a-5p mimic. 
NG: Normal Glucose; HG: High Glucose. All data in the graph represent the mean of 
n= 4 for each sample. Beta-actin (ACTB) is used as endogenous control. miR-146a-5p 
mimic concentration used is 10nM. * indicates a significant difference of ICAM1 








Figure 20 Expression of TNF – α, PPAR–α, ICAM1 in NG and HG+miR-146a-5p 
inhibit. NG: Normal Glucose; HG: High Glucose. All data in the graph represent the 
mean of n= 4 for each sample. Beta-actin (ACTB) is used as endogenous control. miR-
146a-5p inhibitory concentration used is10nM. * indicates a significant difference of 
ICAM1 expression in HG+miR-146a-5p inhibitor vs. NG, P ≤ 0.05. Two tailed p value 
is significant ≤0.05. 
 
Subsequently, TNF - α, PPAR–α, and ICAM1 expression were significantly 
elevated by 15214-folds, 2-folds, and 52-folds, respectively, by transfecting the 
hyperglycemic samples using miR-146a-5p mimic when compared to hyperglycemia 
treatment only, Figure 21. In contrast, silencing of miR-146a-5p using inhibitor 
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Figure 21 Expression of TNF - α, PPAR–α, ICAM1 in HG and HG+miR-146a-5p 
inhibit. HG: High Glucose. All data in the graph represent the mean of n= 4 for each 
sample. Beta-actin (ACTB) is used as endogenous control. miR-146a-5p mimic 
concentration used is 10nM. * indicates a significant difference of TNF - α expression 
in HG+miR-146a-5p mimic vs. HG, P ≤ 0.05. Two tailed p value is significant ≤0.05. 
 
 
Figure 22 Expression of TNF - α, PPAR–α, ICAM1 in HG and HG+miR-146a-5p 
inhibit. HG: High Glucose. All data in the graph represent the mean of n= 4 for each 
sample. Beta-actin (ACTB) is used as endogenous control. miR-146a-5p inhibitor 
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concentration used is10nM. * indicates a significant difference of TNF - α expression 
in HG+miR-146a-5p inhibitor vs. HG, P ≤ 0.05. Two tailed p value is significant ≤0.05. 
 
Finally, a comparison between the transfection of miR-146a-5P mimic and 
inhibitor in hyperglycemia condition was performed. Unexpectedly, no significant 
effect on the expression of TNF – α, PPAR–α, and ICAM1 was demonstrated with 
transfection with miR-146a-5p mimic and inhibit, Figure 23. 
 
 
Figure 23 Expression of TNF – α, PPAR–α, ICAM1 in HG+miR-14a mimic and 
HG+miR-146a-5p inhibit. HG: High Glucose. All data in the graph present the mean 
of n= 4 for each sample. Beta-actin (ACTB) is used as endogenous control. miR-146a-
5p mimic and inhibitory concentration used is 10nM. Two tailed p value is significant 
≤0.05. 
 
B – Effect to a high dose (50 nM) of miR-146a-5p mimic 
Expression of miR-146a-5p 
First, we examined the change in miR-146a-5p when transfecting with 50 nM 
in hyperglycemic conditions. We compared the expression in HG only to the sample 
transfected with 50 nM miR-146a-5p using scramble sequence as a control transfecting 
with 50 nM miR-146a-5p significantly increased the expression of miR-146a-5p gene 
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by 710- fold in comparison with HG sample. Sample transfected with the scramble 
sequence did not show any significant change in miR-146a-5p expression, Figure 24.  
 
 
Figure 24 Quantitative representation of fold change in miR-146a-5p expression 
between HG, HG+ 50 nM miR-14a-5p mimic, and scramble sequence. HG: High 
Glucose; NC: Negative Control (scramble sequences). All data in the graph represent 
the mean of n= 3 for each sample. miR-320a was used as endogenous control. miR-
146a-5p mimic concentration used is 50nM. * indicate a significant difference of miR-
146a-5p expression in HG HRECs treated with 50nM miR-14a-5p mimic vs. HG 
HRECs without treatment, P ≤ 0.05. Two tailed p value is significant ≤0.05. 
 
Genes expression 
Here we assessed the effect of transfecting 50 nM of miR-146a-5p mimic on 
the expression of four genes TNF - α, ICAM 1, PPAR–α, and TRAF6 in HRECs 
exposed to normoglycemia. We found that TNF – α was significantly upregulated by 
3-folds, and TRAF-6 was decreased by 2-folds by 50 nM of miR-146a-5p mimic, while 





Figure 25 Expression of TNF - α, PPAR–α, ICAM1, TRAF6 in NG+miR-14a mimic. 
NG: Normal Glucose. All data in the graph represent the mean of n= 4 for each sample. 
Beta-actin (ACTB) is used as endogenous control. miR-146a-5p mimic concentration 
used is 50nM. * indicate a significant difference of genes expression in NG HRECs 
treated with 50nM miR-14a-5p mimic vs. NG HRECs without treatment, two tailed p 
value is significant ≤0.05. 
 
Then, we studied the effect of 50 nM of miR-146a-5p mimic on the expression 
of four genes TNF - α, ICAM-1, and TRAF6 in HRECs exposed to chronic 
hyperglycemia. Interestingly, the results showed a significant reduction by 8-folds in 
TNF-α, ICAM 1, and TRAF6 expression, while expression was not significantly 





Figure 26 Expression of TNF - α, PPAR–α, ICAM1, TRAF6 in HG+miR-14a mimic. 
HG: High Glucose. All data in the graph represent the mean of n= 4 for each sample. 
Beta-actin (ACTB) is used as endogenous control. miR-146a-5p mimic concentration 
is used 50nM. * indicate a significant difference of genes expression in HG HRECs 
treated with 50nM miR-14a-5p mimic vs. HG HRECs without treatment, two tailed p 
value is significant ≤0.05. 
 
Effect on oxidative stress regulation genes 
In this experiment, we tested the expression level of several important genes 
included in regulating the oxidation stress process: Superoxide dismutase 1 (SOD1), 
Superoxide dismutase 2 (SOD2), Thioredoxin reductase 1 (TXNRD1), 
Chloramphenicol Acetyltransferase (CAT), Glutathione Peroxidase 1 (GPX1) and 
Peroxisome proliferation-activated receptor gamma (PPARγ) as a member of the family 
of ligand-regulated nuclear hormone receptors in hyperglycemia samples transfected 
with 10 nM miR-146a-5p and with 50 nM miR-146a-5p. 
First, we assessed the expression level of the following genes; SOD1, SOD2, 
TXNRD1, CAT, GPX1, and PPARγ in HG cells treated with  10 nM miR-146a-5p, and 
with 50 nM miR-146a-5p and compared to the hyperglycemia samples without 
treatment as a control group, as shown in Figure 27. The results showed significant 
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upregulation in the expression of important anti-oxidative stress genes with transfecting 
50 nM miR-146a-5p;  CAT by 141.8 folds, TXNRD1 by 62 folds, SOD1 by 31 folds, 
and GPX1 by 5.6 folds, while the expression of SOD2 and PPARγ was not affected. 
Transfecting with 10 nM miR-146a-5p increased the expression of two genes only, 
SOD1 and TXNRD1, by approximately 5 folds and 4 folds, respectively. 
 
 
Figure 27 Comparison of expression of genes included regulating oxidative stress 
between 10 nM and 50 nM miR-146a-5p with HG. Expression of SOD1, SOD2, 
TXNRD1, CAT, GPX1, and PPARγ in HG+ 10 nM miR-14a mimic and in HG+ 50 
nM miR-14a mimic in comparison to HG sample. HG: High Glucose. All data in the 
graph represent the mean of n= 3 for each sample. Beta-actin (ACTB) is used as 
endogenous control. miR-146a-5p mimic concentration used are 10nM and 50nM. * 
indicate a significant difference of genes expression in HG HRECs treated with 10nM 
and 50nM miR-14a-5p mimic vs. HG HRECs without treatment, two tailed p value is 
significant ≤0.05. 
 
Then, we assessed the expression level of SOD1, SOD2, TXNRD1, CAT, 
GPX1, and PPARγ genes between 10 nM miR-146a-5p and 50 nM miR-146a-5p in 
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hyperglycemia condition, Figure 28. The results showed significant upregulation in 
anti-oxidative stress genes' expression with transfecting 50 nM miR-146a-5p: CAT by 
83 folds, TXNRD1 by 14 folds, SOD1 by 5.8 folds, and GPX1 by 7.5 folds in 
comparison to 10 nM miR-146a-5p. The finding revealed that 50 nM miR-146a-5p has 
a stronger anti-oxidative effect. 
 
 
Figure 28 Comparison of the expression of genes included in regulating oxidative stress 
between 10 nM and 50 nM miR-146a-5p. Expression of SOD1, SOD2, TXNRD1, 
CAT, GPX1, and PPARγ in HG+ 10 nM miR-14a mimic and in HG+ 50 nM miR-14a 
mimic. HG: High Glucose. All data in the graph represent the mean of n= 3 replicates 
for each sample. Beta-actin (ACTB) is used as endogenous control. miR-146a-5p 
mimic concentration= 10nM and 50nM. * indicate a significant difference of genes 
expression in HG HRECs treated with 50nM miR-14a-5p mimic vs. HG HRECs treated 
with 50nM miR-14a-5p mimic, two tailed p value is significant ≤0.05. 
 
Effect on inflammatory and angiogenesis arrays 
To identify genes or biological pathways, we determined the gene expression 
profiles of cells exposed to hyperglycemia (used as a control group) and cells exposed 
to HG + 50nM mimic miR-146a-5p (used as a treatment group). The cut-off value used 
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for significant expression in the present study was set as expressed fold changes of 2 
and p-value of < 0.05. The expressed fold changes represent data of the treatment group 
(HG+ mimic miRNA) versus the control group (HG), as shown in Table 5. Table 5 
shows a list of differential expressed genes in response to the application of 50nM 
mimic miR-146a-5p to hyperglycemic HRECs (treatment group) compared to HRECs 
exposed to hyperglycemia alone (control). 
 
Table 5 List of angiogenesis and inflammatory panel genes identified by RT-PCR array 
profile, with their cellular location, molecular type, and expressed fold changes in 
hyperglycemic condition response to mimic miR-146a-5p transfection with a final 
concentration of 50nM.  
Symbol Fold 
Change 
Gene Name Location Type (s) 
IL21 10.32 interleukin 21 Extracellular 
Space 
cytokine 







THBS2 7.40 thrombospondin 2 Extracellular 
Space 
other 





IL3 4.59 interleukin 3 Extracellular 
Space 
cytokine 






















TGFB2 3.26 transforming growth 








Gene Name Location Type (s) 
NADPH 3.11   Other chemical - 
endogenous 
mammalian 























ANGPTL4 2.50 angiopoietin like 4 Extracellular 
Space 
other 
PF4 2.32 platelet factor 4 Extracellular 
Space 
cytokine 


















CDH5 2.17 cadherin 5 Plasma 
Membrane 
other 
SERPINE1 2.10 serpin family E member 1 Extracellular 
Space 
other 





PROK2 1.9 prokineticin 2 Extracellular 
Space 
other 
ANG 1.86 angiogenin Extracellular 
Space 
enzyme 














Gene Name Location Type (s) 




FASLG 1.74 Fas ligand Extracellular 
Space 
cytokine 







AKT1 1.62 AKT serine/threonine 
kinase 1 
Cytoplasm kinase 

















EPHB4 1.55 EPH receptor B4 Plasma 
Membrane 
kinase 










ID1 1.51 inhibitor of DNA binding 
1, HLH protein 
Nucleus transcription 
regulator 
NOS3 1.5 nitric oxide synthase 3 Cytoplasm enzyme 
















FLT1 1.34 fms related receptor 
















Gene Name Location Type (s) 
EDN1 1.3 endothelin 1 Extracellular 
Space 
cytokine 
IL17C 1.29 interleukin 17C Extracellular 
Space 
cytokine 










IL16 1.22 interleukin 16 Extracellular 
Space 
cytokine 
IL15 1.16 interleukin 15 Extracellular 
Space 
cytokine 





PLG 1.15 plasminogen Extracellular 
Space 
peptidase 











IL33 1.12 interleukin 33 Extracellular 
Space 
cytokine 
THBS1 1.11 thrombospondin 1 Extracellular 
Space 
other 
FN1 1.1 fibronectin 1 Extracellular 
Space 
enzyme 
IL5 1.09 interleukin 5 Extracellular 
Space 
cytokine 





IFNG 1.02 interferon gamma Extracellular 
Space 
cytokine 
MMP2 1.01 matrix metallopeptidase 2 Extracellular 
Space 
peptidase 
TGFB1 1.01 transforming growth 








Gene Name Location Type (s) 
VEGFB -1.01 vascular endothelial 




























EFNB2 -1.08 ephrin B2 Plasma 
Membrane 
kinase 





NRP2 -1.09 neuropilin 2 Plasma 
Membrane 
kinase 
LTB -1.10 lymphotoxin beta Extracellular 
Space 
cytokine 







CNMD -1.11 tenomodulin Extracellular 
Space 
other 
CCN2 -1.13 cellular communication 









SPHK1 -1.14 sphingosine kinase 1 Cytoplasm kinase 








PDGFA -1.16 platelet derived growth 













Gene Name Location Type (s) 
EGF -1.23 epidermal growth factor Extracellular 
Space 
growth factor 
HIF1A -1.23 hypoxia inducible factor 
1 subunit alpha 
Nucleus transcription 
regulator 





FGF2 -1.28 fibroblast growth factor 2 Extracellular 
Space 
growth factor 









TIE1 -1.34 tyrosine kinase with 
immunoglobulin like and 





endoperoxide synthase 1 
Cytoplasm enzyme 
MMP9 -1.42 matrix metallopeptidase 9 Extracellular 
Space 
peptidase 












IL27 -1.52 interleukin 27 Extracellular 
Space 
cytokine 
PECAM1 -1.53 platelet and endothelial 




TYMP -1.56 thymidine phosphorylase Extracellular 
Space 
growth factor 
OSM -1.57 oncostatin M Extracellular 
Space 
cytokine 




TGFBR1 -1.60 transforming growth 











Gene Name Location Type (s) 





MDK -1.69 midkine Extracellular 
Space 
growth factor 
HPSE -1.71 heparanase Plasma 
Membrane 
enzyme 
EFNA1 -1.72 ephrin A1 Plasma 
Membrane 
other 





IFNA1/IFNA13 -1.74 interferon alpha 1 Extracellular 
Space 
cytokine 
IL17A -1.76 interleukin 17A Extracellular 
Space 
cytokine 





IL1B -1.76 interleukin 1 beta Extracellular 
Space 
cytokine 










ANGPT1 -1.85 angiopoietin 1 Extracellular 
Space 
growth factor 





AIMP1 -1.93 aminoacyl tRNA 
synthetase complex 
interacting 









IFNA2 -2.04 interferon alpha 2 Extracellular 
Space 
cytokine 







Gene Name Location Type (s) 





PGF -2.41 placental growth factor Extracellular 
Space 
growth factor 
IL6 -2.42 interleukin 6 Extracellular 
Space 
cytokine 
VEGFC -2.51 vascular endothelial 











VEGFA -2.83 vascular endothelial 




HGF -2.93 hepatocyte growth factor Extracellular 
Space 
growth factor 
FGF1 -3.00 fibroblast growth factor 1 Extracellular 
Space 
growth factor 




CD40LG -3.26 CD40 ligand Extracellular 
Space 
cytokine 















IL9 -4.35 interleukin 9 Extracellular 
Space 
cytokine 





SERPINF1 -4.84 serpin family F member 1 Extracellular 
Space 
other 
IL7 -5.00 interleukin 7 Extracellular 
Space 
cytokine 









Gene Name Location Type (s) 

















IL1A -6.94 interleukin 1 alpha Extracellular 
Space 
cytokine 










TNF -7.95 tumor necrosis factor Extracellular 
Space 
cytokine 
TNF -7.95 tumor necrosis factor Extracellular 
Space 
cytokine 
TRAF6 -8.00 TNF receptor associated 
factor 6 
Cytoplasm enzyme 











LTA -8.49 lymphotoxin alpha Extracellular 
Space 
cytokine 
VEGFD -9.00 vascular endothelial 




ADGRB1 -9.59 adhesion G protein-











IL17F -14.86 interleukin 17F Extracellular 
Space 
cytokine 
















Gene Name Location Type (s) 
SPP1 -17.71 secreted phosphoprotein 1 Extracellular 
Space 
cytokine 



























The dataset displays 94 downregulated and 96 upregulated genes of both 
inflammatory and angiogenesis panels (Figure 29, 30). Only, twenty-two genes 
displayed fold change above 2, and 33 gens displayed fold change below 2. The Data 
represent the differentially expressed dysregulated genes (DRGs), which were further 
evaluated to obtain details of biological processes, cellular functions, networks, and 
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signaling pathways related to HRECs exposed to hyperglycemia and treated with 50nM 
mimic miR-146a-5p. 





















































































Figure 29 The list of differentially expressed genes of the angiogenesis panel in HRECs 
exposed to hyperglycemia and transfected with 50nM mimic miR-146a-5p compared 
to HRECs treated with only hyperglycemia. Data represent the fold changes in gene 

































































































Figure 30 The list of differentially expressed genes of the inflammatory panel in HRECs 
exposed to hyperglycemia and transfected with 50nM mimic miR-146a-5pcompared to 
HRECs treated with only hyperglycemia. Data represent the fold changes in gene 







To further determine the biological significance and functional classification of 
the genes, bioinformatic tools were used. Metscape enrichment pathways analysis 
(metascape.org) demonstrated the most important enriched terms across the input gene 
lists for pathways and biological process, clustered and colored by p-values as shown 
in Table 6 and  Figure 31. These pathways and biological processes are in order, and 
the top five with percentages were cytokine-cytokine receptor interaction (56.69%), 
angiogenesis (48.41%), chemotaxis (49.04%), positive regulation of locomotion 
(42.04%), Cytokine Signaling in Immune system (42.68%). 
 
Table 6 Top 20 clusters with their representative enriched terms (one per cluster).  Gene 
annotations extracted from the list of all angiogenesis and inflammatory panel genes in 
response to 50nM mimic miR-146a-5p in hyperglycemic conditions of HRECs, relative 
to HRECs treated with HG alone. 
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Figure 31 Bar graph of enriched terms across input gene lists, colored by p-values. 
 
To better understand the detailed mechanisms involved,  identify the primary 
cellular targets that modify endothelial dysfunction of microvascular retinal cells 
exposed to hyperglycemia, and to determine the changes caused by miR-146a-5p 
transfection, the dataset was integrated into Ingenuity Pathway Analysis (IPA) software 
using core analysis. Identifying each gene's role in the data set is important; however, 
the interaction of several genes plays a fundamental role in the outcome of various 
biological, cellular process, and molecular functions and regulations by transcription 
factors, hence important to be identified.  
The most enriched canonical pathways detected in the hyperglycemic 
microvascular endothelial cells in response to transfection by miR-146a-5p based on 
log p value are shown in Table 7 and Figure 32. Notably, the dominant five pathways 
detected in the log p values are Il-17 signaling pathway; Agranulocyte Adhesion; and 
Diapedesis; HMGB1 Signaling; Glucocorticoid Receptor Signaling; and MSP-RON 
Signaling Pathway. As shown in Figure 32 and Table 7, several of these signaling 
pathways affect TRAF6 gene expression. In addition, data obtained from GO analysis 
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indicate that downregulation of the target genes of miR-146a-5p after transfection of 
hyperglycemic HRECs involved many signaling pathways, as indicated in Table 7 such 
as Il-17 signaling pathway, Glucocorticoid Receptor Signaling, IL-8 Signaling, p38 
MAPK Signaling, IL-10 Signaling, Acute Phase Response Signaling, Toll-like 
Receptor Signaling, PPAR Signaling, Th17 Activation Pathway, and IL-6 Signaling. 
These results demonstrate the pleiotropic effects of miR-146a-5p on gene expression 
via different pathways, as displayed in Table 7. 
 
 
Figure 32 Displays a conical illustration of the top 22 significant enriched pathway 
analysis in the HRECs dataset, which is differentially expressed genes transfected with 
50nM of miR-146a-5p mimic. Data are presented as a bar on X-axis. Y-axes indicate 
the log (p-value) of the dataset of the studied genes compared to the IPA knowledge 
base.  
 
Table 7. Top 22 Canonical Pathways of genes of the HRECs transfected with mimic 
miR-146a-5p with their p- values. (Based on Core Analysis in Ingenuity Pathway 
Analysis (IPA). Bold word shown in molecules refers to three target genes evaluated 
after transfection of HRECs with 50nM of miR-146a-5p mimic. Data showed many 









IL-17 Signaling 30 0.106 CCL17, CCL2, CCL22, CD40LG, CSF2, 
CSF3, CXCL1, CXCL3, CXCL5, IL17F, 
IL1A, IL21, IL3, LTA, TGFB2, TNF, 




28.8 0.093 CCL17, CCL2, CCL22, CCL23, CCL24, 
CCL3, CCL4, CCR2, CCR6, CCR8, 
CXCL1, CXCL10, CXCL13, CXCL2, 




17.4 0.0778 CCL2, CD40LG, CSF2, ICAM1, IL17F, 





9.17 0.0203 CCL2, CCL3, CSF2, CXCL3, ICAM1, 





7.05 0.0847 CCL2, CCR2, CSF1, IL3, TNF 




5.77 0.087 CSF2, IL17F, IL21, TNF 
VDR/RXR 
Activation 
4.83 0.0506 CSF2, CXCL10, SPP1, TGFB2 
IL-8 Signaling 4.29 0.0233 CXCL1, ICAM1, IL9, TRAF6, VEGFD 
p38 MAPK 
Signaling 
4.14 0.0339 IL1A, TGFB2, TNF, TRAF6 
Th1 Pathway 4.07 0.0325 CD40LG, ICAM1, LTA, NOTCH4 
LXR/RXR 
Activation 
3.98 0.0308 CCL2, IL1A, SERPINF1, TNF 
STAT3 
Pathway 




3.77 0.0526 CXCL1, LTA, TRAF6 
IL-10 Signaling 3.4 0.0395 IL1A, TNF, TRAF6 
IPA Canonical 
Pathways 











Epigenetic factors involved in response to mimic miR-146a-5p 
miR-146a-5p and transcription factors (TF) 
The binding of miRNAs to 3′ UTR and coding regions of mRNA has silencing 
effects on gene expression. The miRNA interaction with the promoter region has been 
reported to induce transcription. Table 8 shows the most important TF.  
 
Table 8. The transcription factors as upstream regulators in response to transfection of 
hyperglycemic HRECs by miR-146a-5p. Data represent the list of transcription factors, 
z- score of activation or inhibition, overlap p-value, and the target molecules affected 
by these TF as upstream regulators in response to t the transfection of hyperglycemic 





Activation z-score p-value of overlap 
ZNF281 Activated 2.646 9.88E-19 
ZFP36 Activated 2.242 1.1E-15 




3.35 0.038 IL1A, TNF, TRAF6 
Chemokine 
Signaling 
3.27 0.0357 CCL2, CCL24, CCL4 
PPAR Signaling 2.97 0.028 IL1A, TNF, TRAF6 
TNFR2 
Signaling 
2.78 0.0625 LTA, TNF 
Th17 Activation 
Pathway 
2.76 0.0108 CCR6, CSF2, IL17F, IL21, TRAF6 
IL-6 Signaling 2.74 0.0234 IL1A, TNF, TRAF6 
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GFI1 Activated 2.112 1.8E-16 
TWIST2 Activated 2.195 4.62E-06 
FEM1A Activated 2.415 1.91E-12 
KLF2 Activated 2.187 1.28E-56 
BCL6 Activated 2.443 3.34E-19 
GPS2 Activated 2.571 1.97E-07 
HNF4A Activated 2.72  3.95E-5 
BCL3 Activated 3.713 1.33E-21 
NCOA2 Activated 2.044 4.24E-08 
MEOX2 Activated 2.938 3.29E-34 
SIRT1 Activated 2.023 1.57E-15 
ARID1A Activated 2.449 8.66E-07 
CBL Activated 2.003 4.07E-12 
CITED2 Activated 2.795 2.68E-13 
NFAT5 Inhibited -2.118 2.87E-19 
NOTCH4 Inhibited -2.236 7.88E-07 
IRF8 Inhibited -2.32 7.11E-13 
ISL1 Inhibited -2.236 0.000479 4.79E-6 





Activation z-score p-value of overlap 
STAT4 Inhibited -2.396 1.25E-07 
JUN Inhibited -3.312 2.26E-38 
CEBPB Inhibited -2.018 4.55E-23 
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POU5F1 Inhibited -2.178 4.02E-20 
TFEB Inhibited -2.219 2.22E-05 
PML Inhibited -2.183 0.00686 6.86E-5 
IFI16 Inhibited -2.452 3.03E-18 
EGR1 Inhibited -2.194 1.21E-40 
SMAD3 Inhibited -2.239 2.45E-35 
HOXB7 Inhibited -2.043 5.1E-14 
TCF4 Inhibited -2.333 5.78E-07 
NFKB1 Inhibited -2.527 8.82E-46 
RELA Inhibited -3.01 2.24E-46 
BCL10 Inhibited -2.01 3.31E-14 
IRF5 Inhibited -2.036 5.76E-16 
CREBBP Inhibited -2.918 1.52E-15 
HMGB1 Inhibited -3.62 3.79E-25 
 
 
As shown in Table 8, The most important TF involved based on the Z-score of 
activation is MEOX2 (z- score of 2.94), while HMGB1 is the most TF inhibited with 
(z–value of -3.62). Figure 33 shows the most TFs and canonical pathways involved in 
miR-146a-5p regulation. The data clearly indicate that many pathways, TF, and 
intermediate regulators interact to affect the downregulation of TNF expression through 





Figure 33 Regulation of TNF gene expression in response to transfection of 
hyperglycemic HRECs with miR-146a-5p by HMGB1 TF.  Data represent nodes in 
blue indicating the inhibited activity of HMGB1 (blue) as a transcription factor and how 
it cross-talk with other TF and transcription regulators and molecules to affect TNF 
gene expression (green) via different mechanistic pathways and indirect effects in 
response to transfection by mimic miR-146a-5p. Abbreviation; blue arrow= inhibition, 
brown arrow= activation. Solid arrow = active, dot arrow-= weak effect. Blue color of 
nodes = inhibition and orange = activation. Green color of TNF means decreased 
expression. E= expression, LO= localization, A= activation, protein- DNA interaction 
(PD), (P), and transcription (T), causative (C). 
 
Furthermore, in Table 9, the relations exerted by TF HMGB1on molecules in 
the network are shown. 
Table 9 Displays the relationship exerted by the transcription factor HMGB1 on 
molecules of the network in Figure 33. 
From Molecule(s) Relationship Type To Molecule(s) 
HMGB1 activation CCL5 
HMGB1 activation IKBKB 
HMGB1 activation IL1A 
From Molecule(s) Relationship Type To Molecule(s) 
HMGB1 activation Jnk 
HMGB1 activation TNF 
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HMGB1 chemical-protein interactions E. coli lipopolysaccharide 
HMGB1 expression IL1A 
HMGB1 expression TNF 
HMGB1 localization CCL5 
HMGB1 localization IL1A 
HMGB1 localization TNF 
HMGB1 phosphorylation Jnk 
HMGB1 protein-protein interactions TNF 
HMGB1 transcription TNF 
 
 
Further, the pathways and TFs affecting the gene expression of TNF and Il-6 
were investigated, as both genes are downregulated in response to transfection by 
mimic miR-146a-5p (50nM) in hyperglycemic HRECs. Previous data published by our 
lab indicated the critical role of these two molecules in the diabetic complications of 
human subjects (Cheema et al., 2020). Analysis of Figure 34 demonstrates that several 
TFs regulating TNF and IL6, such as Jun, STAT4, NFKB1, and RELA, are inhibited in 
response to miR-146a-5p (50nM) overexpression and by the activated TF MEOX2. 
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Furthermore, involvement of several CP pathways such as apoptosis, PPARα /RXRα, 




Figure 34 Regulation of TNF gene expression in response to transfection of 
hyperglycemic HRECs with miR-146a-5p (50nM) showing the most TFs and canonical 
pathways involved in its regulation. Data represent Nodes in blue indicating inhibited 
activity of JUN, NFKB1, STAT4, RELA (blue), while the increased activity of MEOX2 
(orange) as a transcription factor and how it cross-talk with different canonical 
pathways to affect TNF and IL6 gene expression (green) via different mechanistic 
pathways whether direct and indirect effects in response to transfection by mimic miR-
146a-5p (50nM). Abbreviation; blue arrow= inhibition, brown arrow= activation. Solid 
arrow = active, dot arrow-= weak effect. Blue color of nodes = inhibition and orange = 
activation. Green color of TNF means decreased expression. E= expression, LO= 
localization, A= activation, protein- DNA interaction (PD), (P), and transcription (T), 




Further, we investigated the mechanistic network by which miR-146a-5p exert 
its effects on the downstream target genes, as shown in Figure 35 and Table 10. As 
displayed, the RNA-RNA interactions: microRNA targeting could involve activation 
of activator protein-1, c-Jun (Ap1) as complex Group of TF, which in turn 
downregulates the expression of ICAM1 and VEGFA via different routes such as 
expression, transcription, and protein-DNA interactions. IL10, as is a cytokine that 
affects TNF expression via different mechanisms such as regulation of binding, 
expression, and localization. NFKB1 affects the expression and activation of ICAM1. 
In summary, overexpression of miR-146a-5p (50nM)  in HRECs exposed to high 
glucose affects the expression of several genes of interest in this study, such as TARF6, 
TNF-  IL6, ICAM1, VEGFA, and MMP. These genes are involved in endothelial 
function, such as response to inflammation and angiogenesis. 
 
 
Figure 35 Mechanistic network showing the effect of overexpressed miRNA 146a-5p 
(50nM) in  HRECs on the expression of TRAF6, VEGFA, TNF, MMP9, IL10, and 
ICAM1 genes in hyperglycemic conditions.  Data represent the mechanistic pathways 
by which overexpression of miR-146a-5p regulates the downstream target genes 
TRAF6, VEGFA, TNF, MMP9, IL10, and ICAM1 genes in hyperglycemic conditions. 
Nodes in represent different regulators such as TF; JUN, NFKB1, STAT1, STAT 2, 
IRF1, RELA; ligand-dependent nuclear receptor such as PPARG; complex regulators 
such as NFkB (complex), and how it cross talk to affect the downstream gene 
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expression via different mechanistic pathways whether direct and indirect effects in 
response to transfection by mimic miRNA 146-a. Abbreviation; E= expression, LO= 
localization, A= activation, protein- DNA interaction (PD), (P), and transcription (T), 
causative (C). See legends for molecule type in blue and prediction legend too. See 
Table 10 for more details about relations. 
 
 
Table 10 Displays the relationship exerted by the miR-146a-5p  on molecules of the 
network in Figure 35 
From Molecule(s) Relationship Type To Molecule(s) 
miR-146a-5p  
RNA-RNA interactions: microRNA 
targeting 
TRAF6 
miR-146a-5p  activation Ap1 
miR-146a-5p  activation JUN 
miR-146a-5p  activation 
NFkB 
(complex) 
miR-146a-5p  expression IL6 
miR-146a-5p  expression TNF 
miR-146a-5p  expression TRAF6 
miR-146a-5p  localization IL6 
miR-146a-5p  localization MMP9 
miR-146a-5p  phosphorylation JUN 
 
 
Further, in Figure 36, we explored the IL-8 signaling with crosstalk of miR-
146a-5p (50nM) transfected in HRECs exposed to high glucose. As shown in Figure 
35, the network illustrates the pathways and interactions between IL-8 signaling and 
endothelial functions of HRECs exposed to high glucose after transfection with miR-
146a-5p. IL-8 causes activation of CXCR1/R2, which activates IRAK receptor, which 
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in turn activates TRAF6, while miR-146a-5p downregulates TRAF6 gene expression 
activates IRAK receptor, which activates TRAF6. In contrast, miRNA146a 
downregulates TRAF6 gene expression via its effects on protein-protein interactions 
and ubiquitination of STAT3 inhibition, which in turn causes inhibition of 
angiogenesis. Several pathways are illustrated, such as IL-8 may affect the 
phosphorylation of IκB, which affects the activity of P60NFkB, which in sequence 
affects transcription of Cox2 expression, which causes inhibition of the inflammation 
and downregulates the expression of VCAM1 and ICAM1, which causes inhibition of 




Figure 36 Network displays IL-8 signaling pathway and crosstalk with miR-146a-5p 
on inflammation and angiogenesis functions. Network illustrates the pathways and 
interactions between IL-8 signaling and endothelial functions of HRECs exposed to 
high glucose after transfection with miR-146a-5p (50nM). Il-8 causes activation of 
CXCR1/R2, which activates IRAK receptor, which activates TRAF6, while 
miRNA146a downregulates TRAF6 gene expression that affects protein-protein 
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interactions and ubiquitination of STAT3 inhibition, which in turn causes inhibition of 
angiogenesis. Several pathways are illustrated, such as IL-8 may affect the 
phosphorylation of IκB, which affects the activity of P60NFkB, which in sequence 
affects transcription of Cox2 expression, which causes inhibition of the inflammation 
and downregulates the expression of VCAM1and ICAM1, which causes inhibition of 
















CHAPTER 6: DISCUSSION 
Diabetic retinopathy is a microvascular complication of diabetes and a major 
cause of visual impairment and blindness among the working-age population. The 
stable condition of high blood glucose is the main factor of DR, which activates several 
mechanisms and pathways contributing to disease pathogenesis. Currently, there are 
several therapeutic options; however, the failure of a successful response to these 
available treatments is common among DR patients. A recent approach by researchers 
focuses on studying the effect of miRNAs and gene regulation in DR to develop 
effective molecular therapeutic strategies. One of the widely investigated miRNAs in 
DR is miR-146a-5p which has shown promising anti-inflammatory effects. In this 
study, we assessed the impact of transfecting low and high doses of miR-146a-5p mimic 
and inhibitor on HRECs exposed to hyperglycemia.  
First, in the current study, we did not demonstrate any significant difference in 
cell viability between HRECs exposed to normoglycemia (5.5mM) or to high glucose 
(25mM), which contrasts the findings in other published studies (Bushra, Rizk, & 
Sharma, 2016; Fan, Qiao, & Tang, 2017; S. Jiang & Chen, 2017). However, this 
observation could be due to the difference in the glucose concentration that was used. 
In the current study, we used 25mM, while in the others was 30mM.  S. Jiang & Chen, 
in their study, tested different concentrations of high glucose 22mM and 30mM and 
found that the way high glucose decreases the viability of HREC is dose dependent as 
30mM glucose gradually decreased cell viability. Lower glucose concentration as 
22mM, also reduced cell viability; however, the rate was not significant as compared 
to 30mM glucose  (S. Jiang & Chen, 2017). In addition, HRECs viability was not 
affected with miRNA mimic and inhibitor transfection using the liquid medium 
Lipofectamine RNAiMAX. This finding is very important and shows that the 
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transfection reagents used in this study did not introduce any toxic effect on HRECs. 
Also, in our study, HRECs exposed to high glucose (25mM) for four days did not show 
increased apoptosis rate when compared to normoglycemia, which again was not in line 
with the findings of other published studies (Bushra et al., 2016; X. L. Chen et al., 2013; 
S. Jiang & Chen, 2017). This also could be due to the difference in high glucose 
concentration to which HRECs were exposed between our study and the other studies. 
Another factor could be the inherited properties of the primary cells used in the present 
study compared to other studies. 
Hyperglycemia is reported by numerous studies to have pro-inflammatory, pro-
oxidative, and pro-apoptotic effects. Hyperglycemia is also demonstrated to 
downregulate the expression of miR-146a-5p expression which is well known anti-
inflammatory miRNA. Our findings showed a significant reduction in miR-146a-5p in 
HRECs exposed to high glucose. This finding is supported by other studies performed 
on HRECs and diabetic animal models (S. Chen, Feng, Thomas, & Chakrabarti, 2017; 
P. Zhuang et al., 2017).  
Hence in the current study, the effect of overexpressing and silencing by 
transfecting miR-146a-5p in HRECs exposed to high glucose was assessed. Expression 
of miR-146a-5p is regulated through NF-κB pathway (Jixiang Zhang et al., 2016). As 
a negative feedback mechanism, miR-146a-5p downregulates NF-κB and its 
downstream targets TNF-α and ICAM-1 through targeting the signaling molecules 
IRAK1and TRAF6 (L. Zhang et al., 2020; P. Zhuang et al., 2017). In the current study, 
knockdown miR-146a-5p in HRECs exposed to hyperglycemia in vitro using a dose of 
10nM antimir or inhibitor significantly elevated ROS production, upregulated TNF-α 
ICAM-1 expression, but TRAF 6 expression was not affected. These data enrich the 
published literature that low expression of miR-146a-5p obtained after silencing 
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increases the pro-inflammatory activities (Qiaoyun Gong et al., 2017; Q. Wang et al., 
2014; Y. Xie et al., 2018; E.-A. Ye & Steinle, 2016). This finding demonstrates that 
low expression of miR-146a-5p could highlight the potential role in the pathogenesis 
of DR by enhancing inflammation and oxidative stress in the retina's vascular system 
of diabetic subjects. Further studies are needed to explore in detail these observations 
in vivo using animal models. 
Overexpression of miR-146a-5p in the current study was achieved by 
transfection in vitro of HRECs using two doses of mimic: low dose (10nM) and a high 
dose (50nM). Overexpression of miR-146a-5p using a low dose of 10nM significantly 
elevated ROS production, upregulated the mRNA expression of TNF-α and ICAM-1 
genes in HRECs exposed to hyperglycemia, and consequently, increases the pro-
inflammatory activities. These findings contrast the clue that overexpression of miR-
146a-5p diminishes inflammation and related activities in HRECs exposed to 
hyperglycemia. Cowan et al., in their study, transfected HRECs with 10nM miR-146a-
5p mimic using liquid medium Lipofectamine RNAiMAX similar to the procedure that 
followed in the current study; however, instead of exposing the HRECs to high glucose, 
they treated the cells with 1 or 5 U/mL thrombin which is a strong pro-inflammatory 
factor (Cowan et al., 2014). They found that overexpression of miR-146 with 10 nM 
mimic significantly decreased thrombin's effect on NF-κB expression and the 
downstream inflammatory activities (Cowan et al., 2014). There is a hypothetical 
explanation for this inconsistent finding reported by the current study with the findings 
reported by Cowan et al. The overexpression of miR-146a-5p gene using 10nM was 
insufficient to decrease the massive inflammatory responses and activities that are 
produced by the chronic high glucose condition; however, it was adequate to diminish 
the transient state of inflammation caused by introducing thrombin. This interesting 
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finding could reveal that a small dose of mimic is not enough to maintain homeostasis 
of the negative feedback loop of miR-146a-5p and NF-κB pathway in chronic 
hyperglycemic conditions. 
On the other hand, overexpression of miR-146a-5p using 50nM significantly 
downregulated the expression of TNF-α, ICAM-1, and TRAF6, indicating the anti-
inflammatory and anti-apoptotic role of miR-146a-5p as per the established functions 
of the abovementioned genes. This finding supported that the transfection with a high 
dose 0f 50 nM was optimum to decrease the expression of TRAF6, a well-known target 
gene of miR-146a-5p. The finding of the current study is in line with the data reported 
by numerous published studies supporting the role of miR-146a-5p as an anti-
inflammatory in DR and other vascular complications such as cardiovascular disorder 
and nephropathy (Luly et al., 2019; J. Xie et al., 2017; E.-A. Ye & Steinle, 2016; P. 
Zhuang et al., 2017).  Since we were unable to assess the oxidative stress by measuring 
ROS production level, we examined the expression of six important genes involved in 
the oxidation process, which are SOD1, SOD2, TXNRD1 CAT, GPX1, and PPARγ in 
HRECs exposed to hyperglycemia and transfected with 10 nM and 50nM for 48 hours. 
The HRECs transfected with 50nM mimic of miR-146a-5p demonstrated significant 
upregulation in the expression of four genes, CAT, TXNRD1, SOD1, and GPX1, in 
comparison with the low dose of transfection using 10nM mimic. These data reveal the 
antioxidant function of overexpressed miR-146a-5p with 50nM mimic and its anti-
inflammatory and anti-apoptotic roles. It also supports the data mentioned above that 
overexpression of miR-146a-5p with a low dose of mimic using 10nM increases ROS 
production. It can enhance oxidative stress due to the impaired upregulation of the 
expression of genes involved in the anti-oxidative process except for SOD1, and 
TXNRD1 which are significantly upregulated. 
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Following that, profiling arrays were performed to assess the effect of 
overexpression of miR-146a-5p using 50nM on inflammatory and angiogenesis gene 
expression to understand the potential mechanisms for anti-inflammatory and anti-
angiogenesis function. We compared the HRECs cells exposed to high glucose as a 
control group compared to HRECs cells transfected with a high dose of 50nM mimic 
under high glucose conditions. The inflammatory profile showed a significant reduction 
in several genes notably, secreted phosphoprotein 1 (SSP1), IL17C, CXCL2, CXCL13, 
CXCL1, and CX3CR1. SSP1 gene has been reported to be present in sclerotium tissues 
only (M. Li & Rollins, 2009). This could be an interesting gene to examine further since 
the environment in the diabetic retina is vulnerable to hemorrhage with the process of 
neovascularization. The rest of the inflammatory genes dysregulated are chemokines 
and GM-CSF, which are well established to function in inflammatory conditions. 
The angiogenesis profile supported the RT-PCR results of the current study and 
showed that overexpression miR-14a-5p using 50nM function through downregulating 
the expression of all the VEGF isomers: VEGFA, VEGFB, VEGFC, VEGFD/ FIGF in 
addition to TNF, ICAM1, TRAF6, and Adhesion G Protein-Coupled Receptor 
B1(ADGRB1). The two significantly most downregulated genes were VEGFD/ FIGF, 
a gene that has an important role in endothelial cell growth and proliferation, and 
ADGRB1, an angiogenesis gene associated with several diseases such as Glioblastoma. 
Overexpression miR-14a-5p specifically upregulated Thrombospondin-2 (THBS2) 
gene expression, a protein that regulates various cell interactions and functions as an 
anti-angiogenesis factor. 
We initially hypothetically assumed that miR-146a-5p might regulate 
inflammation through PPAR-α. Our data showed no significant increase in PPAR-α 
expression in samples transfected with the 50nM of miR-146a-5p mimic. From the 
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results of inflammatory and angiogenesis gene arrays, we concluded that miR-146a-5p 
mediate its anti-inflammatory and anti-angiogenesis functions through targeting 
TRAF6 and, consequently, the downstream factors such as protein-protein interactions 
and ubiquitination of STAT3 inhibition, which in turn causes inhibition of 
angiogenesis. Figure 37 summarizes the findings of the study regarding pathways and 
molecules affected by miR-146a-5p. 
 
Figure 37 Summary of pathways and molecules targeted by miR-146a-5p in 




CHAPTER 7: CONCLUSION 
In conclusion, our data strengthen and add to the current literature regarding the 
anti-inflammatory role of miR-146a-5p in DR and hypothetically in other vascular 
complications of diabetes. To summarize, the findings of the current study revealed that 
overexpressing of miR-146a-5p using 50nM decreases the expression level of pro-
inflammatory, anti-apoptotic, anti-angiogenesis, and antioxidant genes, and hence 
inhibiting the inflammatory activities and the followed process which are involved in 
progressing and developing DR. The current study also shows the importance of 
determining the optimal effective dose of mimic to overexpress miR-146a-5p – in the 
current study 50nM showed to be optimum -, as using ineffective doses may result in 
adverse effects. Therefore, further comprehensive studies and dose-time curve 
experiments would help determine the effective therapeutic dose of miR-146a-5p that 




LIMITATIONS AND FUTURE STUDIES 
The present study has numerous limitations which need future investigations. 
Since we could not find data regarding the proper dose of miR-146a-5p mimic and 
inhibitor in the published studies, we initially started our experiments with 10 nM. The 
10 nM miR-146a-5p mimic on cells exposed to chronic hyperglycemia at a 
concentration of 25 mM glucose showed a pro-inflammatory effect which contrasts 
what is published in the literature, hence we performed a small size pilot experiment to 
study the effect of a higher dose, and the 50 nM miR-146a-5p mimic demonstrated anti-
inflammatory effect in cells exposed to chronic hyperglycemia. We recommend doing 
further studies to test the effect of more than a few doses of miR-146a-5p mimic (e.g. 
5 nM, 10 nM, 30 nM, 50 nM, 100 nM) with different transfection periods (e.g. 24, 48, 
72 hours) to establish dose/time curves. Also, the study aimed to assess the expression 
of the inflammatory proteins using western blot (WB); however, restrictions related to 
the SARS-COV-2 pandemic, which affected the reagents shipping, made it impossible 
to perform the test before the submission due date. Hence, we recommend evaluating 
the effect of miR-146a-5p on TNF – α and ICAM1 expression in future studies. Finally, 
due to the time constraint, we could not study the interaction between miR-146a-5p and 
the other miRNAs, which may have a potential role in regulating inflammation. 
Therefore, we recommend evaluating the HG + miR-146a-5p samples for the 
expression of miRNAs expression to identify and solve the puzzle of mechanisms and 
interaction of potential miRNAs regulating DR pathogenesis. 
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NG 289.7 2.11 8.1 
NG + miR-146a-5p 
mimic  
110.1 1.85 7.9 
Mannitol 296.8 1.93 .8 
HG 225.3 1.81 8.2 
HG + miR-146a-5p 
mimic  
169.1 1.92 9.1 
HG + miR-146a-5p 
mimic NC 
246.7 2.01 8 
HG + miR-146a-5p 
inhibit 
294.3 1.84 8.2 
HG + miR-146a-5p 
inhibit NC 
211.6 1.82 8.6 
NG + miR-146a-5p 
mimic + TNF-α 
224.3 1.81 8.9 




APPENDIX C: Genes included in Inflammatory genes Array 
 
Position Symbol Gene Name 
A01 AIMP1 
Aminoacyl tRNA synthetase complex-interacting 
multifunctional protein 1  
A02 BMP2 Bone morphogenetic protein 2  
A03 C5 Complement component 5  
A04 CCL1 Chemokine (C-C motif) ligand 1  
A05 CCL11 Chemokine (C-C motif) ligand 11  
A06 CCL13 Chemokine (C-C motif) ligand 13  
A07 CCL15 Chemokine (C-C motif) ligand 15  
A08 CCL16 Chemokine (C-C motif) ligand 16  
A09 CCL17 Chemokine (C-C motif) ligand 17  
A10 CCL2 Chemokine (C-C motif) ligand 2  
A11 CCL20 Chemokine (C-C motif) ligand 20  
A12 CCL22 Chemokine (C-C motif) ligand 22  
B01 CCL23 Chemokine (C-C motif) ligand 23  
B02 CCL24 Chemokine (C-C motif) ligand 24  
B03 CCL26 Chemokine (C-C motif) ligand 26  
B04 CCL3 Chemokine (C-C motif) ligand 3  
B05 CCL4 Chemokine (C-C motif) ligand 4  
B06 CCL5 Chemokine (C-C motif) ligand 5  
B07 CCL7 Chemokine (C-C motif) ligand 7  
B08 CCL8 Chemokine (C-C motif) ligand 8  
B09 CCR1 Chemokine (C-C motif) receptor 1  
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Position Symbol Gene Name 
B10 CCR2 Chemokine (C-C motif) receptor 2  
B11 CCR3 Chemokine (C-C motif) receptor 3  
B12 CCR4 Chemokine (C-C motif) receptor 4  
C01 CCR5 Chemokine (C-C motif) receptor 5  
C02 CCR6 Chemokine (C-C motif) receptor 6  
C03 CCR8 Chemokine (C-C motif) receptor 8  
C04 CD40LG CD40 ligand  
C05 CSF1 Colony stimulating factor 1 (macrophage)  
C06 CSF2 Colony stimulating factor 2 (granulocyte-macrophage)  
C07 CSF3 Colony stimulating factor 3 (granulocyte)  
C08 CX3CL1 Chemokine (C-X3-C motif) ligand 1  
C09 CX3CR1 Chemokine (C-X3-C motif) receptor 1  
C10 CXCL1 
Chemokine (C-X-C motif) ligand 1 (melanoma growth 
stimulating activity, alpha)  
C11 CXCL10 Chemokine (C-X-C motif) ligand 10  
C12 CXCL11 Chemokine (C-X-C motif) ligand 11  
D01 CXCL12 Chemokine (C-X-C motif) ligand 12  
D02 CXCL13 Chemokine (C-X-C motif) ligand 13  
D03 CXCL2 Chemokine (C-X-C motif) ligand 2  
D04 CXCL3 Chemokine (C-X-C motif) ligand 3  
D05 CXCL5 Chemokine (C-X-C motif) ligand 5  
D06 CXCL6 
Chemokine (C-X-C motif) ligand 6 (granulocyte 
chemotactic protein 2)  
D07 CXCL9 Chemokine (C-X-C motif) ligand 9  
D08 CXCR1 Chemokine (C-X-C motif) receptor 1  
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Position Symbol Gene Name 
D09 CXCR2 Chemokine (C-X-C motif) receptor 2  
D10 FASLG Fas ligand (TNF superfamily, member 6)  
D11 IFNA2 Interferon, alpha 2  
D12 IFNG Interferon, gamma  
E01 IL10RA Interleukin 10 receptor, alpha  
E02 IL10RB Interleukin 10 receptor, beta  
E03 IL13 Interleukin 13  
E04 IL15 Interleukin 15  
E05 IL16 Interleukin 16  
E06 IL17A Interleukin 17A  
E07 IL17C Interleukin 17C  
E08 IL17F Interleukin 17F  
E09 IL1A Interleukin 1, alpha  
E10 IL1B Interleukin 1, beta  
E11 IL1R1 Interleukin 1 receptor, type I  
E12 IL1RN Interleukin 1 receptor antagonist  
F01 IL21 Interleukin 21  
F02 IL27 Interleukin 27  
F03 IL3 Interleukin 3 (colony-stimulating factor, multiple)  
F04 IL33 Interleukin 33  
F05 IL5 Interleukin 5 (colony-stimulating factor, eosinophil)  
F06 IL5RA Interleukin 5 receptor, alpha  
F07 IL7 Interleukin 7  
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Position Symbol Gene Name 
F08 CXCL8 Interleukin 8  
F09 IL9 Interleukin 9  
F10 IL9R Interleukin 9 receptor  
F11 LTA Lymphotoxin alpha (TNF superfamily, member 1)  
F12 LTB Lymphotoxin beta (TNF superfamily, member 3)  
G01 MIF 
Macrophage migration inhibitory factor (glycosylation-
inhibiting factor)  
G02 NAMPT Nicotinamide phosphoribosyl transferase  
G03 OSM Oncostatin M  
G04 SPP1 Secreted phosphoprotein 1  




















Tumor necrosis factor (ligand) superfamily, member 13b  
G11 TNFSF4 Tumor necrosis factor (ligand) superfamily, member 4  




APPENDIX D: Genes included in Angiogenesis genes Array 
Position Symbol Description  
A01 AKT1 V-akt murine thymoma viral oncogene homolog 1  
A02 ANG Angiogenin, ribonuclease, RNase A family, 5  
A03 ANGPT1 Angiopoietin 1  
A04 ANGPT2 Angiopoietin 2  
A05 ANGPTL4 Angiopoietin-like 4  
A06 ANPEP Alanyl (membrane) aminopeptidase  
A07 ADGRB1 Brain-specific angiogenesis inhibitor 1  
A08 CCL11 Chemokine (C-C motif) ligand 11  
A09 CCL2 Chemokine (C-C motif) ligand 2  
A10 CDH5 Cadherin 5, type 2 (vascular endothelium)  
A11 COL18A1 Collagen, type XVIII, alpha 1  
A12 COL4A3 Collagen, type IV, alpha 3 (Goodpasture antigen)  
B01 CTGF Connective tissue growth factor  
B02 CXCL1 
Chemokine (C-X-C motif) ligand 1 (melanoma growth 
stimulating activity, alpha)  
B03 CXCL10 Chemokine (C-X-C motif) ligand 10  
B04 CXCL5 Chemokine (C-X-C motif) ligand 5  
B05 CXCL6 
Chemokine (C-X-C motif) ligand 6 (granulocyte chemotactic 
protein 2)  
B06 CXCL9 Chemokine (C-X-C motif) ligand 9  
B07 EDN1 Endothelin 1  
B08 EFNA1 Ephrin-A1  
B09 EFNB2 Ephrin-B2  
B10 EGF Epidermal growth factor  
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Position Symbol Description  
B11 ENG Endoglin  
B12 EPHB4 EPH receptor B4  
C01 ERBB2 
V-erb-b2 erythroblastic leukemia viral oncogene homolog 2, 
neuro/glioblastoma derived oncogene homolog (avian)  
C02 F3 Coagulation factor III (thromboplastin, tissue factor)  
C03 FGF1 Fibroblast growth factor 1 (acidic)  
C04 FGF2 Fibroblast growth factor 2 (basic)  
C05 FGFR3 Fibroblast growth factor receptor 3  
C06 FIGF 
C-fos induced growth factor (vascular endothelial growth 
factor D)  
C07 FLT1 
Fms-related tyrosine kinase 1 (vascular endothelial growth 
factor/vascular permeability factor receptor)  
C08 FN1 Fibronectin 1  
C09 HGF Hepatocyte growth factor (hepapoietin A; scatter factor)  
C10 HIF1A 
Hypoxia inducible factor 1, alpha subunit (basic helix-loop-
helix transcription factor)  
C11 HPSE Heparanase  
C12 ID1 
Inhibitor of DNA binding 1, dominant negative helix-loop-
helix protein  
D01 IFNA1 Interferon, alpha 1  
D02 IFNG Interferon, gamma  
D03 IGF1 Insulin-like growth factor 1 (somatomedin C)  
D04 IL1B Interleukin 1, beta  
D05 IL6 Interleukin 6 (interferon, beta 2)  
D06 CXCL8 Interleukin 8  
D07 ITGAV 
Integrin, alpha V (vitronectin receptor, alpha polypeptide, 
antigen CD51)  
D08 ITGB3 Integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61)  
D09 JAG1 Jagged 1  
 
115 
Position Symbol Description  
D10 KDR 
Kinase insert domain receptor (a type III receptor tyrosine 
kinase)  
D11 LECT1 Leukocyte cell derived chemotaxin 1  
D12 LEP Leptin  
E01 MDK Midkine (neurite growth-promoting factor 2)  
E02 MMP14 Matrix metallopeptidase 14 (membrane-inserted)  
E03 MMP2 
Matrix metallopeptidase 2 (gelatinase A, 72kDa gelatinase, 
72kDa type IV collagenase)  
E04 MMP9 
Matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 
92kDa type IV collagenase)  
E05 NOS3 Nitric oxide synthase 3 (endothelial cell)  
E06 NOTCH4 Notch 4  
E07 NRP1 Neuropilin 1  
E08 NRP2 Neuropilin 2  
E09 PDGFA Platelet-derived growth factor alpha polypeptide  
E10 PECAM1 Platelet/endothelial cell adhesion molecule  
E11 PF4 Platelet factor 4  
E12 PGF Placental growth factor  
F01 PLAU Plasminogen activator, urokinase  
F02 PLG Plasminogen  
F03 PROK2 Prokineticin 2  
F04 PTGS1 
Prostaglandin-endoperoxide synthase 1 (prostaglandin G/H 
synthase and cyclooxygenase)  
F05 S1PR1 Sphingosine-1-phosphate receptor 1  
F06 SERPINE1 
Serpin peptidase inhibitor, clade E (nexin, plasminogen 
activator inhibitor type 1), member 1  
F07 SERPINF1 
Serpin peptidase inhibitor, clade F (alpha-2 antiplasmin, 
pigment epithelium derived factor), member 1  
F08 SPHK1 Sphingosine kinase 1  
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Position Symbol Description  
F09 TEK TEK tyrosine kinase, endothelial  
F10 TGFA Transforming growth factor, alpha  
F11 TGFB1 Transforming growth factor, beta 1  
F12 TGFB2 Transforming growth factor, beta 2  
G01 TGFBR1 Transforming growth factor, beta receptor 1  
G02 THBS1 Thrombospondin 1  
G03 THBS2 Thrombospondin 2  
G04 TIE1 
Tyrosine kinase with immunoglobulin-like and EGF-like 
domains 1  
G05 TIMP1 TIMP metallopeptidase inhibitor 1  
G06 TIMP2 TIMP metallopeptidase inhibitor 2  
G07 TIMP3 TIMP metallopeptidase inhibitor 3  
G08 TNF Tumor necrosis factor  
G09 TYMP Thymidine phosphorylase  
G10 VEGFA Vascular endothelial growth factor A  
G11 VEGFB Vascular endothelial growth factor B  





Abougalambou, S. S. I., & Abougalambou, A. S. (2015). Risk factors associated with 
diabetic retinopathy among type 2 diabetes patients at teaching hospital in 
Malaysia. Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 9(2), 
98-103. doi:https://doi.org/10.1016/j.dsx.2014.04.019 
Adamis, A. P., Shima, D. T., Yeo, K. T., Yeo, T. K., Brown, L. F., Berse, B., . . . 
Folkman, J. (1993). Synthesis and Secretion of Vascular Permeability 
Factor/Vascular Endothelial Growth Factor by Human Retinal Pigment 
Epithelial Cells. Biochemical and Biophysical Research Communications, 
193(2), 631-638. doi:https://doi.org/10.1006/bbrc.1993.1671 
Al-Kharashi, A. S. (2018). Role of oxidative stress, inflammation, hypoxia and 
angiogenesis in the development of diabetic retinopathy. Saudi J Ophthalmol, 
32(4), 318-323. doi:10.1016/j.sjopt.2018.05.002 
Al-Sadeq, D. W. (2018). The Expression of Retinal miRNA Evoked by Hyperglycemia 
and After Adiponectin Treatment in Human Retinal Endothelial Cells.  
Amit-Cohen, B.-C., Rahat, M., & Rahat, M. (2013). Tumor cell-macrophage 
interactions increase angiogenesis through secretion of EMMPRIN. Frontiers 
in Physiology, 4, 178.  
Aplin, A. C., Gelati, M., Fogel, E., Carnevale, E., & Nicosia, R. F. (2006). 
Angiopoietin-1 and vascular endothelial growth factor induce expression of 
inflammatory cytokines before angiogenesis. Physiological Genomics, 27(1), 
20-28. doi:10.1152/physiolgenomics.00048.2006 
Bansal, P., Gupta, R., & Kotecha, M. (2013, 2013 October-December). Frequency of 
diabetic retinopathy in patients with diabetes mellitus and its correlation with 
 
118 
duration of diabetes mellitus. Medical Journal of Dr. D.Y. Patil University, 6(4), 
366.  
Barot, M., Gokulgandhi, M. R., Patel, S., & Mitra, A. K. (2013). Microvascular 
complications and diabetic retinopathy: recent advances and future 
implications. Future medicinal chemistry, 5(3), 301-314. 
doi:10.4155/fmc.12.206 
Birben, E., Sahiner, U. M., Sackesen, C., Erzurum, S., & Kalayci, O. (2012). Oxidative 
stress and antioxidant defense. The World Allergy Organization journal, 5(1), 
9-19. doi:10.1097/WOX.0b013e3182439613 
Bordet, R., Ouk, T., Petrault, O., Gelé, P., Gautier, S., Laprais, M., . . . Bastide, M. 
(2006). PPAR: a new pharmacological target for neuroprotection in stroke and 
neurodegenerative diseases. Biochem Soc Trans, 34(Pt 6), 1341-1346. 
doi:10.1042/bst0341341 
Bushra, S., Rizk, N., & Sharma, I. (2016). ASSOCIATION BETWEEN INSULIN 
AND NITRIC OXIDE IN HUMAN RETINAL MICROVASCULAR 
ENDOTHELIAL CELLS IN VITRO. Investigative Ophthalmology & Visual 
Science, 57(12), 5426-5426.  
Busik, J. V., Mohr, S., & Grant, M. B. (2008). Hyperglycemia-induced reactive oxygen 
species toxicity to endothelial cells is dependent on paracrine mediators. 
Diabetes, 57(7), 1952-1965. doi:10.2337/db07-1520 
Calderon, G. D., Juarez, O. H., Hernandez, G. E., Punzo, S. M., & De la Cruz, Z. D. 
(2017). Oxidative stress and diabetic retinopathy: development and treatment. 
Eye (Lond), 31(8), 1122-1130. doi:10.1038/eye.2017.64 
Caporali, A., & Emanueli, C. (2011). MicroRNA regulation in angiogenesis. Vascular 
Pharmacology, 55(4), 79-86. doi:https://doi.org/10.1016/j.vph.2011.06.006 
 
119 
Catalanotto, C., Cogoni, C., & Zardo, G. (2016). MicroRNA in Control of Gene 
Expression: An Overview of Nuclear Functions. International journal of 
molecular sciences, 17(10), 1712. doi:10.3390/ijms17101712 
Cavarretta, E., & Frati, G. (2016). MicroRNAs in Coronary Heart Disease: Ready to 
Enter the Clinical Arena? BioMed Research International, 2016, 2150763. 
doi:10.1155/2016/2150763 
Cheema, A. K., Kaur, P., Fadel, A., Younes, N., Zirie, M., & Rizk, N. M. (2020). 
Integrated Datasets of Proteomic and Metabolomic Biomarkers to Predict Its 
Impacts on Comorbidities of Type 2 Diabetes Mellitus. Diabetes Metab Syndr 
Obes, 13, 2409-2431. doi:10.2147/dmso.s244432 
Chen, L., Deng, H., Cui, H., Fang, J., Zuo, Z., Deng, J., . . . Zhao, L. (2017). 
Inflammatory responses and inflammation-associated diseases in organs. 
Oncotarget, 9(6), 7204-7218. doi:10.18632/oncotarget.23208 
Chen, N., Wang, J., Hu, Y., Cui, B., Li, W., Xu, G., . . . Liu, S. (2014). MicroRNA-410 
reduces the expression of vascular endothelial growth factor and inhibits 
oxygen-induced retinal neovascularization. PLoS One, 9(4), e95665-e95665. 
doi:10.1371/journal.pone.0095665 
Chen, S., Feng, B., Thomas, A. A., & Chakrabarti, S. (2017). miR-146a regulates 
glucose induced upregulation of inflammatory cytokines extracellular matrix 
proteins in the retina and kidney in diabetes. PLOS ONE, 12(3), e0173918. 
doi:10.1371/journal.pone.0173918 
Chen, W., Esselman, W. J., Jump, D. B., & Busik, J. V. (2005). Anti-inflammatory 
effect of docosahexaenoic acid on cytokine-induced adhesion molecule 
expression in human retinal vascular endothelial cells. Investigative 
 
120 
Ophthalmology & Visual Science, 46(11), 4342-4347. doi:10.1167/iovs.05-
0601 
Chen, X. L., Zhang, X. D., Li, Y. Y., Chen, X. M., Tang, D. R., & Ran, R. J. (2013). 
Involvement of HMGB1 mediated signalling pathway in diabetic retinopathy: 
evidence from type 2 diabetic rats and ARPE-19 cells under diabetic condition. 
Br J Ophthalmol, 97(12), 1598-1603. doi:10.1136/bjophthalmol-2013-303736 
Cohen, S. R., & Gardner, T. W. (2016). Diabetic Retinopathy and Diabetic Macular 
Edema. Dev Ophthalmol, 55, 137-146. doi:10.1159/000438970 
Condorelli, G., Latronico, M., & Cavarretta, E. (2014). microRNAs in Cardiovascular 
Diseases Current Knowledge and the Road Ahead. Journal of the American 
College of Cardiology, 63. doi:10.1016/j.jacc.2014.01.050 
Cornel, S., Adriana, I. D., Mihaela, T. C., Speranta, S., Algerino, D. S., Mehdi, B., & 
Jalaladin, H.-R. (2015). Anti-vascular endothelial growth factor indications in 
ocular disease. Romanian journal of ophthalmology, 59(4), 235-242.  
Cowan, C., Muraleedharan, C. K., O'Donnell, J. J., 3rd, Singh, P. K., Lum, H., Kumar, 
A., & Xu, S. (2014). MicroRNA-146 inhibits thrombin-induced NF-κB 
activation and subsequent inflammatory responses in human retinal endothelial 
cells. Invest Ophthalmol Vis Sci, 55(8), 4944-4951. doi:10.1167/iovs.13-13631 
Cristina, M., Adina, M., Simona Georgiana, P., Valerica, T., & Maria, M. (2013). 
Biochemistry of hyperglycemia induced vascular dysfunction. Romanian 
Journal of Diabetes Nutrition and Metabolic Diseases, 20(4), 419-425. 
doi:https://doi.org/10.2478/rjdnmd-2013-0042 
Curtale, G., Citarella, F., Carissimi, C., Goldoni, M., Carucci, N., Fulci, V., . . . Macino, 
G. (2010). An emerging player in the adaptive immune response: microRNA-
 
121 
146a is a modulator of IL-2 expression and activation-induced cell death in T 
lymphocytes. Blood, 115(2), 265-273. doi:10.1182/blood-2009-06-225987 
Dantas da Costa E Silva, M. E., Polina, E. R., Crispim, D., Sbruzzi, R. C., Lavinsky, 
D., Mallmann, F., . . . Dos Santos, K. G. (2019). Plasma levels of miR-29b and 
miR-200b in type 2 diabetic retinopathy. Journal of cellular and molecular 
medicine, 23(2), 1280-1287. doi:10.1111/jcmm.14030 
Das, A., Ganesh, K., Khanna, S., Sen, C. K., & Roy, S. (2014). Engulfment of apoptotic 
cells by macrophages: a role of microRNA-21 in the resolution of wound 
inflammation. Journal of immunology (Baltimore, Md. : 1950), 192(3), 1120-
1129. doi:10.4049/jimmunol.1300613 
de Pontual, L., Yao, E., Callier, P., Faivre, L., Drouin, V., Cariou, S., . . . Amiel, J. 
(2011). Germline deletion of the miR-17∼92 cluster causes skeletal and growth 
defects in humans. Nature genetics, 43(10), 1026-1030. doi:10.1038/ng.915 
dell'Omo, R., Semeraro, F., Bamonte, G., Cifariello, F., Romano, M. R., & Costagliola, 
C. (2013). Vitreous mediators in retinal hypoxic diseases. Mediators of 
Inflammation, 2013, 935301-935301. doi:10.1155/2013/935301 
Duh, E. J., Sun, J. K., & Stitt, A. W. (2017). Diabetic retinopathy: current 
understanding, mechanisms, and treatment strategies. JCI insight, 2(14), 
e93751. doi:10.1172/jci.insight.93751 
Evans, J., Michelessi, M., & Virgili, G. (2014). Laser photocoagulation for proliferative 
diabetic retinopathy. The Cochrane database of systematic reviews, 11, 
CD011234. doi:10.1002/14651858.CD011234.pub2 
Fabbri, M., Paone, A., Calore, F., Galli, R., Gaudio, E., Santhanam, R., . . . Croce, C. 
M. (2012). MicroRNAs bind to Toll-like receptors to induce prometastatic 
inflammatory response. Proceedings of the National Academy of Sciences of the 
 
122 
United States of America, 109(31), E2110-E2116. 
doi:10.1073/pnas.1209414109 
Fan, C., Qiao, Y., & Tang, M. (2017). Notoginsenoside R1 attenuates high glucose-
induced endothelial damage in rat retinal capillary endothelial cells by 
modulating the intracellular redox state. Drug Des Devel Ther, 11, 3343-3354. 
doi:10.2147/dddt.s149700 
Fang, S., Ma, X., Guo, S., & Lu, J. (2017). MicroRNA-126 inhibits cell viability and 
invasion in a diabetic retinopathy model via targeting IRS-1. Oncol Lett, 14(4), 
4311-4318. doi:10.3892/ol.2017.6695 
Fasanaro, P., D'Alessandra, Y., Di Stefano, V., Melchionna, R., Romani, S., Pompilio, 
G., . . . Martelli, F. (2008). MicroRNA-210 modulates endothelial cell response 
to hypoxia and inhibits the receptor tyrosine kinase ligand Ephrin-A3. The 
Journal of biological chemistry, 283(23), 15878-15883. 
doi:10.1074/jbc.M800731200 
Fiedler, J., Jazbutyte, V., Kirchmaier Bettina, C., Gupta Shashi, K., Lorenzen, J., 
Hartmann, D., . . . Thum, T. (2011). MicroRNA-24 Regulates Vascularity After 
Myocardial Infarction. Circulation, 124(6), 720-730. 
doi:10.1161/CIRCULATIONAHA.111.039008 
Fish, J. E., Santoro, M. M., Morton, S. U., Yu, S., Yeh, R.-F., Wythe, J. D., . . . 
Srivastava, D. (2008). miR-126 regulates angiogenic signaling and vascular 
integrity. Developmental cell, 15(2), 272-284. 
doi:10.1016/j.devcel.2008.07.008 
Friedman, R. C., Farh, K. K.-H., Burge, C. B., & Bartel, D. P. (2009). Most mammalian 




Fu, Z., & Tindall, D. J. (2008). FOXOs, cancer and regulation of apoptosis. Oncogene, 
27(16), 2312-2319. doi:10.1038/onc.2008.24 
Gong, Q., & Su, G. (2017). Roles of miRNAs and long noncoding RNAs in the 
progression of diabetic retinopathy. Biosci Rep, 37(6). 
doi:10.1042/bsr20171157 
Gong, Q., Xie, J. n., Liu, Y., Li, Y., & Su, G. (2017). Differentially Expressed 
MicroRNAs in the Development of Early Diabetic Retinopathy. Journal of 
Diabetes Research, 2017, 4727942. doi:10.1155/2017/4727942 
Group, B. D. W., Atkinson Jr, A. J., Colburn, W. A., DeGruttola, V. G., DeMets, D. L., 
Downing, G. J., . . . Schooley, R. T. (2001). Biomarkers and surrogate 
endpoints: preferred definitions and conceptual framework. Clinical 
Pharmacology & Therapeutics, 69(3), 89-95.  
Guo, R., Gu, J., Zhang, Z., Wang, Y., & Gu, C. (2015). MicroRNA-410 functions as a 
tumor suppressor by targeting angiotensin II type 1 receptor in pancreatic 
cancer. IUBMB Life, 67(1), 42-53. doi:10.1002/iub.1342 
He, L., & Hannon, G. J. (2004). MicroRNAs: small RNAs with a big role in gene 
regulation. Nature Reviews Genetics, 5(7), 522-531. doi:10.1038/nrg1379 
Heij, E., Tecim, S., Kessels, A., Liem, A., Japing, W., & Hendrikse, F. (2004). Clinical 
variables and their relation to visual outcome after vitrectomy in eyes with 
diabetic retinal traction detachment. Graefe's archive for clinical and 
experimental ophthalmology = Albrecht von Graefes Archiv für klinische und 
experimentelle Ophthalmologie, 242, 210-217. doi:10.1007/s00417-003-0815-
5 
IDF. (2019). IDF DIABETES ATLAS. Retrieved from https://diabetesatlas.org/en/ 
 
124 
Israelian-Konaraki, Z., & Reaven, P. D. (2005). Peroxisome Proliferator-Activated 
Receptor-Alpha and Atherosclerosis: From Basic Mechanisms to Clinical 
Implications. Cardiology, 103(1), 1-9. doi:10.1159/000081845 
Jiang, Q., Lyu, X.-M., Yuan, Y., & Wang, L. (2017). Plasma miR-21 expression: an 
indicator for the severity of Type 2 diabetes with diabetic retinopathy. 
Bioscience reports, 37(2), BSR20160589. doi:10.1042/BSR20160589 
Jiang, Q., Zhao, F., Liu, X., Li, R., & Liu, J. (2015). Effect of miR-200b on retinal 
endothelial cell function under high glucose environment. International journal 
of clinical and experimental pathology, 8, 10482-10487.  
Jiang, S., & Chen, X. (2017). HMGB1 siRNA can reduce damage to retinal cells 
induced by high glucose in vitro and in vivo. Drug design, development and 
therapy, 11, 783-795. doi:10.2147/DDDT.S129913 
Khalfaoui, T., Lizard, G., & Ouertani-Meddeb, A. (2008). Adhesion molecules (ICAM-
1 and VCAM-1) and diabetic retinopathy in type 2 diabetes. Journal of 
Molecular Histology, 39(2), 243-249. doi:10.1007/s10735-007-9159-5 
Khurana, R., Simons, M., Martin John, F., & Zachary Ian, C. (2005). Role of 
Angiogenesis in Cardiovascular Disease. Circulation, 112(12), 1813-1824. 
doi:10.1161/CIRCULATIONAHA.105.535294 
Kim, Y., & Park, C. W. (2019). Mechanisms of Adiponectin Action: Implication of 
Adiponectin Receptor Agonism in Diabetic Kidney Disease. International 
journal of molecular sciences, 20(7), 1782. doi:10.3390/ijms20071782 
Knoepp, K., Teske, R., Korte, L., Dutzmann, J., Rieckmann, M., Daniel, J. M., . . . 
Sedding, D. G. (2020). MicroRNA-146a regulates angiogenesis and functional 




Kollias, A. N., & Ulbig, M. W. (2010). Diabetic retinopathy: Early diagnosis and 
effective treatment. Deutsches Arzteblatt international, 107(5), 75-84. 
doi:10.3238/arztebl.2010.0075 
Konstantinidis, L., Carron, T., de Ancos, E., Chinet, L., Hagon-Traub, I., Zuercher, E., 
& Peytremann-Bridevaux, I. (2017). Awareness and practices regarding eye 
diseases among patients with diabetes: a cross sectional analysis of the CoDiab-
VD cohort. BMC endocrine disorders, 17(1), 56-56. doi:10.1186/s12902-017-
0206-2 
Kreth, S., Hübner, M., & Hinske, L. C. (2018). MicroRNAs as Clinical Biomarkers and 
Therapeutic Tools in Perioperative Medicine. Anesthesia & Analgesia, 126(2).  
Krol, J., Loedige, I., & Filipowicz, W. (2010). The widespread regulation of microRNA 
biogenesis, function and decay. Nature Reviews Genetics, 11(9), 597-610. 
doi:10.1038/nrg2843 
Kuehbacher, A., Urbich, C., Zeiher Andreas, M., & Dimmeler, S. (2007). Role of Dicer 
and Drosha for Endothelial MicroRNA Expression and Angiogenesis. 
Circulation research, 101(1), 59-68. doi:10.1161/CIRCRESAHA.107.153916 
Kumarswamy, R., Volkmann, I., & Thum, T. (2011). Regulation and function of 
miRNA-21 in health and disease. RNA biology, 8(5), 706-713. 
doi:10.4161/rna.8.5.16154 
Kwon, H., & Pessin, J. E. (2013). Adipokines mediate inflammation and insulin 
resistance. Frontiers in endocrinology, 4, 71-71. doi:10.3389/fendo.2013.00071 
Leasher, J., Bourne, R., Flaxman, S., Jonas, J., Keeffe, J., Naidoo, K., . . . Taylor, H. 
(2016). Global Estimates on the Number of People Blind or Visually Impaired 




Li, E.-H., Huang, Q.-Z., Li, G.-C., Xiang, Z.-Y., & Zhang, X. (2017). Effects of 
miRNA-200b on the development of diabetic retinopathy by targeting VEGFA 
gene. Bioscience reports, 37(2), BSR20160572. doi:10.1042/BSR20160572 
Li, M., & Rollins, J. A. (2009). The development-specific protein (Ssp1) from 
Sclerotinia sclerotiorum is encoded by a novel gene expressed exclusively in 
sclerotium tissues. Mycologia, 101(1), 34-43. doi:10.3852/08-114 
Li, Y., & Shi, X. (2013). MicroRNAs in the regulation of TLR and RIG-I pathways. 
Cellular & molecular immunology, 10(1), 65-71. doi:10.1038/cmi.2012.55 
Liu, C.-H., Huang, S., Britton, W. R., & Chen, J. (2020). MicroRNAs in Vascular Eye 
Diseases. International journal of molecular sciences, 21(2), 649. 
doi:10.3390/ijms21020649 
Liu, Y., Song, Y., Tao, L., Qiu, W., Lv, H., Jiang, X., . . . Li, X. (2017). Prevalence of 
diabetic retinopathy among 13473 patients with diabetes mellitus in China: a 
cross-sectional epidemiological survey in six provinces. BMJ open, 7(1), 
e013199-e013199. doi:10.1136/bmjopen-2016-013199 
Lu, Q., Zhang, J., Zhao, N., Wang, H., Tong, Q., & Wang, S. (2017). Association of 
IL-6 Gene (-174 and -572 G/C) Polymorphisms with Proliferative Diabetic 
Retinopathy of Type 2 Diabetes in a Chinese Population. Ophthalmic Research, 
58(3), 162-167. doi:10.1159/000475670 
Luly, F. R., Lévêque, M., Licursi, V., Cimino, G., Martin-Chouly, C., Théret, N., . . . 
Del Porto, P. (2019). MiR-146a is over-expressed and controls IL-6 production 




Ma, X., Becker Buscaglia, L. E., Barker, J. R., & Li, Y. (2011). MicroRNAs in NF-
kappaB signaling. Journal of molecular cell biology, 3(3), 159-166. 
doi:10.1093/jmcb/mjr007 
Madsen-Bouterse, S., Mohammad, G., & Kowluru, R. A. (2010). Glyceraldehyde-3-
phosphate dehydrogenase in retinal microvasculature: implications for the 
development and progression of diabetic retinopathy. Investigative 
Ophthalmology & Visual Science, 51(3), 1765-1772. doi:10.1167/iovs.09-4171 
Magliah, S. F., Bardisi, W., Al Attah, M., & Khorsheed, M. M. (2018). The prevalence 
and risk factors of diabetic retinopathy in selected primary care centers during 
the 3-year screening intervals. Journal of family medicine and primary care, 
7(5), 975-981. doi:10.4103/jfmpc.jfmpc_85_18 
Mahesh, G., & Biswas, R. (2019). MicroRNA-155: A Master Regulator of 
Inflammation. Journal of interferon & cytokine research : the official journal 
of the International Society for Interferon and Cytokine Research, 39(6), 321-
330. doi:10.1089/jir.2018.0155 
Maier, M. M. J. A. M. (2006). Angiogenesis: An Overview: New Frontiers in 
Angiogenesis. Springer, Dordrecht. 
Mancuso, P. (2016). The role of adipokines in chronic inflammation. ImmunoTargets 
and therapy, 5, 47-56. doi:10.2147/ITT.S73223 
Martinez, B., & Peplow, P. V. (2019). MicroRNAs as biomarkers of diabetic 
retinopathy and disease progression. Neural regeneration research, 14(11), 
1858-1869. doi:10.4103/1673-5374.259602 
Mastropasqua, R., Toto, L., Cipollone, F., Santovito, D., Carpineto, P., & 
Mastropasqua, L. (2014). Role of microRNAs in the modulation of diabetic 
 
128 
retinopathy. Progress in retinal and eye research, 43, 92-107. 
doi:10.1016/j.preteyeres.2014.07.003 
Mazzeo, A., Beltramo, E., Lopatina, T., Gai, C., Trento, M., & Porta, M. (2018). 
Molecular and functional characterization of circulating extracellular vesicles 
from diabetic patients with and without retinopathy and healthy subjects. 
Experimental Eye Research, 176, 69-77. 
doi:https://doi.org/10.1016/j.exer.2018.07.003 
McArthur, K., Feng, B., Wu, Y., Chen, S., & Chakrabarti, S. (2011). MicroRNA-200b 
regulates vascular endothelial growth factor-mediated alterations in diabetic 
retinopathy. Diabetes, 60(4), 1314-1323. doi:10.2337/db10-1557 
Meissner, M., Stein, M., Urbich, C., Reisinger, K., Suske, G., Staels, B., . . . Gille, J. 
(2004). PPARalpha activators inhibit vascular endothelial growth factor 
receptor-2 expression by repressing Sp1-dependent DNA binding and 
transactivation. Circulation research, 94(3), 324-332. 
doi:10.1161/01.res.0000113781.08139.81 
Metin, T., Dinç, E., Görür, A., Erdoğan, S., Ertekin, S., Sarı, A. A., . . . Çelik, Y. (2018). 
Evaluation of the plasma microRNA levels in stage 3 premature retinopathy 
with plus disease: preliminary study. Eye (London, England), 32(2), 415-420. 
doi:10.1038/eye.2017.193 
Mohamed, Q., Gillies, M. C., & Wong, T. Y. (2007). Management of Diabetic 
RetinopathyA Systematic Review. JAMA, 298(8), 902-916. 
doi:10.1001/jama.298.8.902 
Musat, O., Cernat, C., Labib, M., Gheorghe, A., Toma, O., Zamfir, M., & Boureanu, 
A. M. (2015). DIABETIC MACULAR EDEMA. Romanian journal of 
ophthalmology, 59(3), 133-136.  
 
129 
Negi, G., Kumar, A., Joshi, R., P K, R., & Sharma, S. (2011). Oxidative stress and 
diabetic neuropathy: Current status of antioxidants. IIOAB Journal, 2, 71-78.  
Nejad, C., Stunden, H. J., & Gantier, M. P. (2018). A guide to miRNAs in inflammation 
and innate immune responses. The FEBS Journal, 285(20), 3695-3716. 
doi:10.1111/febs.14482 
Nentwich, M. M., & Ulbig, M. W. (2015). Diabetic retinopathy - ocular complications 
of diabetes mellitus. World journal of diabetes, 6(3), 489-499. 
doi:10.4239/wjd.v6.i3.489 
Noda, K., Nakao, S., Ishida, S., & Ishibashi, T. (2012). Leukocyte Adhesion Molecules 
in Diabetic Retinopathy. Journal of ophthalmology, 2012, 279037. 
doi:10.1155/2012/279037 
O'Connell, R., Rao, D., Chaudhuri, A., & Baltimore, D. (2010). Physiological and 
pathological roles of microRNAs in the immune system. Nature reviews. 
Immunology, 10, 111-122. doi:10.1038/nri2708 
Osada, H., & Takahashi, T. (2007). MicroRNAs in biological processes and 
carcinogenesis. Carcinogenesis, 28(1), 2-12. doi:10.1093/carcin/bgl185 
Otrock, Z. K., Mahfouz, R. A. R., Makarem, J. A., & Shamseddine, A. I. (2007). 
Understanding the biology of angiogenesis: Review of the most important 
molecular mechanisms. Blood Cells, Molecules, and Diseases, 39(2), 212-220. 
doi:https://doi.org/10.1016/j.bcmd.2007.04.001 
Otsuka, M., Zheng, M., Hayashi, M., Lee, J.-D., Yoshino, O., Lin, S., & Han, J. (2008). 
Impaired microRNA processing causes corpus luteum insufficiency and 




Palazzo, A. F., & Lee, E. S. (2015). Non-coding RNA: what is functional and what is 
junk? Frontiers in genetics, 6, 2-2. doi:10.3389/fgene.2015.00002 
Park, J. E., Keller, G. A., & Ferrara, N. (1993). The vascular endothelial growth factor 
(VEGF) isoforms: differential deposition into the subepithelial extracellular 
matrix and bioactivity of extracellular matrix-bound VEGF. Molecular biology 
of the cell, 4(12), 1317-1326. doi:10.1091/mbc.4.12.1317 
Qin, L.-L., An, M.-X., Liu, Y.-L., Xu, H.-C., & Lu, Z.-Q. (2017). MicroRNA-126: a 
promising novel biomarker in peripheral blood for diabetic retinopathy. 
International journal of ophthalmology, 10(4), 530-534. 
doi:10.18240/ijo.2017.04.05 
Qing, S., Yuan, S., Yun, C., Hui, H., Mao, P., Wen, F., . . . Liu, Q. (2014). Serum 
MiRNA Biomarkers serve as a Fingerprint for Proliferative Diabetic 
Retinopathy. Cellular Physiology and Biochemistry, 34(5), 1733-1740. 
doi:10.1159/000366374 
Rezk, N. A., Sabbah, N. A., & Saad, M. S. S. (2016). Role of MicroRNA 126 in 
screening, diagnosis, and prognosis of diabetic patients in Egypt. IUBMB Life, 
68(6), 452-458. doi:10.1002/iub.1502 
Romano, G. L., Platania, C. B. M., Drago, F., Salomone, S., Ragusa, M., Barbagallo, 
C., . . . Bucolo, C. (2017). Retinal and Circulating miRNAs in Age-Related 
Macular Degeneration: An In vivo Animal and Human Study. Frontiers in 
pharmacology, 8, 168-168. doi:10.3389/fphar.2017.00168 
Roy, S., Kern, T. S., Song, B., & Stuebe, C. (2017). Mechanistic Insights into 
Pathological Changes in the Diabetic Retina: Implications for Targeting 




Rungger-Brändle, E., Dosso, A. A., & Leuenberger, P. (2000). Glial Reactivity, an 
Early Feature of Diabetic Retinopathy. Investigative Ophthalmology & Visual 
Science, 41, 1971-1980.  
Rübsam, A., Parikh, S., & Fort, P. E. (2018). Role of Inflammation in Diabetic 
Retinopathy. Int J Mol Sci, 19(4). doi:10.3390/ijms19040942 
Rübsam, A., Parikh, S., & Fort, P. E. (2018). Role of Inflammation in Diabetic 
Retinopathy. International journal of molecular sciences, 19(4), 942. 
doi:10.3390/ijms19040942 
Sakurai, E., Taguchi, H., Anand, A., Ambati, B. K., Gragoudas, E. S., Miller, J. W., . . 
. Ambati, J. (2003). Targeted Disruption of the CD18 or ICAM-1 Gene Inhibits 
Choroidal Neovascularization. Investigative Ophthalmology & Visual Science, 
44(6), 2743-2749. doi:10.1167/iovs.02-1246 
Santos, J. M., Tewari, S., & Kowluru, R. A. (2012). A compensatory mechanism 
protects retinal mitochondria from initial insult in diabetic retinopathy. Free 
radical biology & medicine, 53(9), 1729-1737. 
doi:10.1016/j.freeradbiomed.2012.08.588 
Sheedy, F. J. (2015). Turning 21: Induction of miR-21 as a Key Switch in the 
Inflammatory Response. Frontiers in Immunology, 6, 19.  
Shibuya, M. (2011). Vascular Endothelial Growth Factor (VEGF) and Its Receptor 
(VEGFR) Signaling in Angiogenesis: A Crucial Target for Anti- and Pro-
Angiogenic Therapies. Genes & cancer, 2(12), 1097-1105. 
doi:10.1177/1947601911423031 
Silva, V. A. O., Polesskaya, A., Sousa, T. A., Corrêa, V. M. A., André, N. D., Reis, R. 
I., . . . De Lucca, F. L. (2011). Expression and cellular localization of 
microRNA-29b and RAX, an activator of the RNA-dependent protein kinase 
 
132 
(PKR), in the retina of streptozotocin-induced diabetic rats. Molecular vision, 
17, 2228-2240.  
Simó, R., & Hernández, C. (2009). Advances in the medical treatment of diabetic 
retinopathy. Diabetes care, 32(8), 1556-1562. doi:10.2337/dc09-0565 
Singh, R., & Mo, Y.-Y. (2013). Role of microRNAs in breast cancer. Cancer biology 
& therapy, 14(3), 201-212. doi:10.4161/cbt.23296 
Solomon, S. D., Chew, E., Duh, E. J., Sobrin, L., Sun, J. K., VanderBeek, B. L., . . . 
Gardner, T. W. (2017). Diabetic Retinopathy: A Position Statement by the 
American Diabetes Association. Diabetes care, 40(3), 412-418. 
doi:10.2337/dc16-2641 
Song, J., Ouyang, Y., Che, J., Li, X., Zhao, Y., Yang, K., . . . Yuan, W. (2017). Potential 
Value of miR-221/222 as Diagnostic, Prognostic, and Therapeutic Biomarkers 
for Diseases. Frontiers in Immunology, 8, 56.  
Sorrentino, F. S., Matteini, S., Bonifazzi, C., Sebastiani, A., & Parmeggiani, F. (2018). 
Diabetic retinopathy and endothelin system: microangiopathy versus 
endothelial dysfunction. Eye (Lond), 32(7), 1157-1163. doi:10.1038/s41433-
018-0032-4 
Srivastava, S., Zaidi, A., Afreen, S., Eba, A., shwar, M., & Raza, S. (2019). 
DIAGNOSTIC IMPORTANCE OF MIRNA IN DIABETIC RETINOPATHY. 
Era's Journal of Medical Research, 6, 131-138. doi:10.24041/ejmr2019.143 
Stewart, M. W. (2016). Treatment of diabetic retinopathy: Recent advances and 
unresolved challenges. World journal of diabetes, 7(16), 333-341. 
doi:10.4239/wjd.v7.i16.333 
Su, Z. F., Sun, Z. W., Zhang, Y., Wang, S., Yu, Q. G., & Wu, Z. B. (2017). Regulatory 
effects of miR-146a/b on the function of endothelial progenitor cells in acute 
 
133 
ischemic stroke in mice. Kaohsiung J Med Sci, 33(8), 369-378. 
doi:10.1016/j.kjms.2017.05.010 
Sun, J. K., Lin, M. M., Lammer, J., Prager, S., Sarangi, R., Silva, P. S., & Aiello, L. P. 
(2014). Disorganization of the Retinal Inner Layers as a Predictor of Visual 
Acuity in Eyes With Center-Involved Diabetic Macular Edema. JAMA 
Ophthalmology, 132(11), 1309-1316. doi:10.1001/jamaophthalmol.2014.2350 
Suárez, Y., & Sessa, W. C. (2009). MicroRNAs as novel regulators of angiogenesis. 
Circulation research, 104(4), 442-454. 
doi:10.1161/CIRCRESAHA.108.191270 
Taganov, K., Boldin, M., & Baltimore, D. (2007). MicroRNAs and Immunity: Tiny 
Players in a Big Field. Immunity, 26, 133-137. 
doi:10.1016/j.immuni.2007.02.005 
Taganov, K. D., Boldin, M. P., Chang, K.-J., & Baltimore, D. (2006). NF-kappaB-
dependent induction of microRNA miR-146, an inhibitor targeted to signaling 
proteins of innate immune responses. Proceedings of the National Academy of 
Sciences of the United States of America, 103(33), 12481-12486. 
doi:10.1073/pnas.0605298103 
Tan, G. S., Ikram, M. K., Sabanayagam, C., Neelam, K., Lamoureux, E. L., Tai, E. S., 
. . . Wong, T. Y. (2014). Serum levels of Leptin and Adiponectin are associated 
with diabetic retinopathy in an Asian population with diabetes mellitus. 
Investigative Ophthalmology & Visual Science, 55(13), 5344-5344.  
Tang, J., & Kern, T. S. (2011). Inflammation in diabetic retinopathy. Progress in retinal 
and eye research, 30(5), 343-358. doi:10.1016/j.preteyeres.2011.05.002 
 
134 
Tarr, J. M., Kaul, K., Chopra, M., Kohner, E. M., & Chibber, R. (2013). 
Pathophysiology of diabetic retinopathy. ISRN ophthalmology, 2013, 343560-
343560. doi:10.1155/2013/343560 
Thomas, R. L., Halim, S., Gurudas, S., Sivaprasad, S., & Owens, D. R. (2019). IDF 
Diabetes Atlas: A review of studies utilising retinal photography on the global 
prevalence of diabetes related retinopathy between 2015 and 2018. Diabetes 
research and clinical practice, 157, 107840.  
Usui, Y., Westenskow, P. D., Murinello, S., Dorrell, M. I., Scheppke, L., Bucher, F., . 
. . Friedlander, M. (2015). Angiogenesis and Eye Disease. Annual Review of 
Vision Science, 1(1), 155-184. doi:10.1146/annurev-vision-082114-035439 
Vujosevic, S., Micera, A., Bini, S., Berton, M., Esposito, G., & Midena, E. (2015). 
Aqueous Humor Biomarkers of Müller Cell Activation in Diabetic Eyes. 
Investigative Ophthalmology & Visual Science, 56(6), 3913-3918. 
doi:10.1167/iovs.15-16554 
Vujosevic, S., Micera, A., Bini, S., Berton, M., Esposito, G., & Midena, E. (2016). 
Proteome analysis of retinal glia cells-related inflammatory cytokines in the 
aqueous humour of diabetic patients. Acta Ophthalmologica, 94(1), 56-64. 
doi:10.1111/aos.12812 
Wang, Q., Bozack, S. N., Yan, Y., Boulton, M. E., Grant, M. B., & Busik, J. V. (2014). 
Regulation of retinal inflammation by rhythmic expression of MiR-146a in 
diabetic retina. Investigative Ophthalmology & Visual Science, 55(6), 3986-
3994. doi:10.1167/iovs.13-13076 
Wang, Q., Navitskaya, S., Chakravarthy, H., Huang, C., Kady, N., Lydic, T. A., . . . 
Busik, J. V. (2016). Dual Anti-Inflammatory and Anti-Angiogenic Action of 
 
135 
miR-15a in Diabetic Retinopathy. EBioMedicine, 11, 138-150. 
doi:10.1016/j.ebiom.2016.08.013 
Wang, S., Aurora, A. B., Johnson, B. A., Qi, X., McAnally, J., Hill, J. A., . . . Olson, E. 
N. (2008). The endothelial-specific microRNA miR-126 governs vascular 
integrity and angiogenesis. Developmental cell, 15(2), 261-271. 
doi:10.1016/j.devcel.2008.07.002 
Wang, S., & Olson, E. N. (2009). AngiomiRs--key regulators of angiogenesis. Current 
opinion in genetics & development, 19(3), 205-211. 
doi:10.1016/j.gde.2009.04.002 
Wang, W., & Lo, A. C. Y. (2018). Diabetic Retinopathy: Pathophysiology and 
Treatments. Int J Mol Sci, 19(6). doi:10.3390/ijms19061816 
Wang, Y., Yuan, Y., & Jiang, H. (2014). Serum and vitreous levels of visfatin in 
patients with diabetic retinopathy. Medical science monitor : international 
medical journal of experimental and clinical research, 20, 2729-2732. 
doi:10.12659/MSM.891292 
Weinreb, R. N., Aung, T., & Medeiros, F. A. (2014). The pathophysiology and 
treatment of glaucoma: a review. JAMA, 311(18), 1901-1911. 
doi:10.1001/jama.2014.3192 
Whitehead, M., Wickremasinghe, S., Osborne, A., Van Wijngaarden, P., & Martin, K. 
R. (2018). Diabetic retinopathy: a complex pathophysiology requiring novel 
therapeutic strategies. Expert Opin Biol Ther, 18(12), 1257-1270. 
doi:10.1080/14712598.2018.1545836 
Xie, J., Ikram, M. K., Cotch, M. F., Klein, B., Varma, R., Shaw, J. E., . . . Wong, T. Y. 
(2017). Association of Diabetic Macular Edema and Proliferative Diabetic 
Retinopathy With Cardiovascular Disease: A Systematic Review and Meta-
 
136 
analysis. JAMA Ophthalmol, 135(6), 586-593. 
doi:10.1001/jamaophthalmol.2017.0988 
Xie, Y., Chu, A., Feng, Y., Chen, L., Shao, Y., Luo, Q., . . . Chen, Y. (2018). 
MicroRNA-146a: A Comprehensive Indicator of Inflammation and Oxidative 
Stress Status Induced in the Brain of Chronic T2DM Rats. Frontiers in 
Pharmacology, 9, 478.  
Yang, T. T., Song, S. J., Xue, H. B., Shi, D. F., Liu, C. M., & Liu, H. (2015). Regulatory 
T cells in the pathogenesis of type 2 diabetes mellitus retinopathy by miR-155. 
European review for medical and pharmacological sciences, 19, 2010-2015.  
Yang, W., Yang, D., Na, S., Sandusky, G., Zhang, Q., & Zhao, G. (2005). Dicer Is 
Required for Embryonic Angiogenesis during Mouse Development. The 
Journal of biological chemistry, 280, 9330-9335. doi:10.1074/jbc.M413394200 
Yau, J. W. Y., Rogers, S. L., Kawasaki, R., Lamoureux, E. L., Kowalski, J. W., Bek, 
T., . . . Meta-Analysis for Eye Disease Study, G. (2012). Global prevalence and 
major risk factors of diabetic retinopathy. Diabetes care, 35(3), 556-564. 
doi:10.2337/dc11-1909 
Ye, E.-A., & Steinle, J. J. (2016). miR-146a Attenuates Inflammatory Pathways 
Mediated by TLR4/NF-<i>κ</i>B and TNF<i>α</i> to Protect Primary Human 
Retinal Microvascular Endothelial Cells Grown in High Glucose. Mediators of 
Inflammation, 2016, 3958453. doi:10.1155/2016/3958453 
Ye, E.-A., & Steinle, J. J. (2017a). miR-146a suppresses STAT3/VEGF pathways and 
reduces apoptosis through IL-6 signaling in primary human retinal 
microvascular endothelial cells in high glucose conditions. Vision research, 
139, 15-22. doi:10.1016/j.visres.2017.03.009 
 
137 
Ye, E.-A., & Steinle, J. J. (2017b). Regulatory role of microRNA on inflammatory 
responses of diabetic retinopathy. Neural regeneration research, 12(4), 580-
581. doi:10.4103/1673-5374.205095 
Ye, J., Guo, R., Shi, Y., Qi, F., Guo, C., & Yang, L. (2016). miR-155 Regulated 
Inflammation Response by the SOCS1-STAT3-PDCD4 Axis in Atherogenesis. 
Mediators of Inflammation, 2016, 8060182-8060182. 
doi:10.1155/2016/8060182 
Yee, D., Shah, K. M., Coles, M. C., Sharp, T. V., & Lagos, D. (2017). MicroRNA-155 
induction via TNF-α and IFN-γ suppresses expression of programmed death 
ligand-1 (PD-L1) in human primary cells. The Journal of biological chemistry, 
292(50), 20683-20693. doi:10.1074/jbc.M117.809053 
Yilmaz, M., Sonmez, A., Acikel, C., Celik, T., Bingol, N., Pinar, M., . . . Ozata, M. 
(2004). Adiponectin may play a part in the pathogenesis of diabetic retinopathy. 
European journal of endocrinology / European Federation of Endocrine 
Societies, 151, 135-140. doi:10.1530/eje.0.1510135 
Yoshida, S., Yoshida, A., & Ishibashi, T. (2004). Induction of IL-8, MCP-1, and bFGF 
by TNF-α in retinal glial cells: implications for retinal neovascularization 
during post-ischemic inflammation. Graefe's Archive for Clinical and 
Experimental Ophthalmology, 242(5), 409-413. doi:10.1007/s00417-004-0874-
2 
Yun, J. S., Lim, T. S., Cha, S. A., Ahn, Y. B., Song, K. H., Choi, J. A., . . . Ko, S. H. 
(2016). Clinical Course and Risk Factors of Diabetic Retinopathy in Patients 




Zaki, W. M. D. W., Zulkifley, M. A., Hussain, A., Halim, W. H. W. A., Mustafa, N. B. 
A., & Ting, L. S. (2016). Diabetic retinopathy assessment: Towards an 
automated system. Biomedical Signal Processing and Control, 24, 72-82. 
doi:https://doi.org/10.1016/j.bspc.2015.09.011 
Zampetaki, A., Willeit, P., Burr, S., Yin, X., Langley, S. R., Kiechl, S., . . . Mayr, M. 
(2016). Angiogenic microRNAs Linked to Incidence and Progression of 
Diabetic Retinopathy in Type 1 Diabetes. Diabetes, 65(1), 216. 
doi:10.2337/db15-0389 
Zhang, J., Wang, X., Vikash, Ye, Q., Wu, D., Liu, Y., & Dong, W. (2016). ROS and 
ROS-mediated cellular signaling. Oxidative Medicine and Cellular Longevity, 
2016 (2016). doi:10.1155/2016/4350965 
Zhang, J., Wu, L., Chen, J., Lin, S., Cai, D., Chen, C., & Chen, Z. (2018). 
Downregulation of MicroRNA 29a/b exacerbated diabetic retinopathy by 
impairing the function of Müller cells via Forkhead box protein O4. Diab Vasc 
Dis Res, 15(3), 214-222. doi:10.1177/1479164118756239 
Zhang, L., Dong, L., Tang, Y., Li, M., & Zhang, M. (2020). MiR-146b protects against 
the inflammation injury in pediatric pneumonia through MyD88/NF-κB 
signaling pathway. Infectious Diseases, 52(1), 23-32. 
doi:10.1080/23744235.2019.1671987 
Zhou, Q., Gallagher, R., Ufret-Vincenty, R., Li, X., Olson, E. N., & Wang, S. (2011). 
Regulation of angiogenesis and choroidal neovascularization by members of 
microRNA-23~27~24 clusters. Proceedings of the National Academy of 




Zhu, K., Pan, Q., Zhang, X., Kong, L.-Q., Fan, J., Dai, Z., . . . Zhou, J. (2013). MiR-
146a enhances angiogenic activity of endothelial cells in hepatocellular 
carcinoma by promoting PDGFRA expression. Carcinogenesis, 34(9), 2071-
2079. doi:10.1093/carcin/bgt160 
Zhuang, P., Muraleedharan, C. K., & Xu, S. (2017). Intraocular Delivery of miR-146 
Inhibits Diabetes-Induced Retinal Functional Defects in Diabetic Rat Model. 
Investigative Ophthalmology & Visual Science, 58(3), 1646-1655. 
doi:10.1167/iovs.16-21223 
Zhuang, Z., Xiao, q., Hu, H., Tian, S.-y., Lu, Z.-j., Zhang, T.-z., & Bai, Y.-l. (2015). 
Down-regulation of microRNA-155 attenuates retinal neovascularization via 
the PI3K/Akt pathway. Molecular vision, 21, 1173-1184.  
Zorena, K., Jachimowicz-Duda, O., Ślęzak, D., Robakowska, M., & Mrugacz, M. 
(2020). Adipokines and Obesity. Potential Link to Metabolic Disorders and 
Chronic Complications. International journal of molecular sciences, 21(10), 
3570. doi:10.3390/ijms21103570 
Zou, H.-L., Wang, Y., Gang, Q., Zhang, Y., & Sun, Y. (2017). Plasma level of miR-93 
is associated with higher risk to develop type 2 diabetic retinopathy. Graefe's 
Archive for Clinical and Experimental Ophthalmology, 255(6), 1159-1166. 
doi:10.1007/s00417-017-3638-5 
Zuazo-Gaztelu, I., & Casanovas, O. (2018). Unraveling the Role of Angiogenesis in 
Cancer Ecosystems. Frontiers in Oncology, 8, 248.  
Zur, D., Iglicki, M., & Loewenstein, A. (2019). The Role of Steroids in the Management 
of Diabetic Macular Edema. Ophthalmic Research, 62(4), 231-236. 
doi:10.1159/000499540 
 
